

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 04:38:08 ON 29 MAY 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 04:38:25 ON 29 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2

DICTIONARY FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\posullivan\183zza.str

L1 STRUCTURE UPLOADED

=>

Uploading C:\posullivan\183zzb.str

L2 STRUCTURE UPLOADED

=>


Uploading C:\posullivan\183zzc.str

L3 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 12  
L2 HAS NO ANSWERS  
L2 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> d 13  
L3 HAS NO ANSWERS  
L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 04:48:25 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 187 TO 773  
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1

```

=> search l1
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 04:48:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      385 TO ITERATE

100.0% PROCESSED      385 ITERATIONS      1 ANSWERS
SEARCH TIME: 00.00.01

L5      1 SEA SSS FUL L1

=> s l2
SAMPLE SEARCH INITIATED 04:48:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      24 TO ITERATE

100.0% PROCESSED      24 ITERATIONS      0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   187 TO      773
PROJECTED ANSWERS:      0 TO        0

L6      0 SEA SSS SAM L2

=> search l2
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 04:48:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      385 TO ITERATE

100.0% PROCESSED      385 ITERATIONS      5 ANSWERS
SEARCH TIME: 00.00.01

L7      5 SEA SSS FUL L2

=> s l3
SAMPLE SEARCH INITIATED 04:48:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      24 TO ITERATE

100.0% PROCESSED      24 ITERATIONS      0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   187 TO      773
PROJECTED ANSWERS:      0 TO        0

L8      0 SEA SSS SAM L3

=> search l3
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 04:49:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      385 TO ITERATE

100.0% PROCESSED      385 ITERATIONS      0 ANSWERS
SEARCH TIME: 00.00.01

L9      0 SEA SSS FUL L3

=> s l5 or l7
L10     6 L5 OR L7

```

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
523.05	523.26

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 04:49:26 ON 29 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 May 2007 VOL 146 ISS 23  
FILE LAST UPDATED: 28 May 2007 (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l10

L11 5 L10

=> d l11 fbib ab hitstr 1-5

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:547250 CAPLUS

DN 143:77956

TI Preparation of bis-aryl sulfonamides as potent modulators of chemokine receptors

IN Ungashe, Solomon; Wei, Zheng; Wright, J. J.; Pennell, Andrew; Premack, Brett; Schall, Thomas

PA USA

SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 716,183.  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2005137179	A1	20050623	US 2004-848836	20040519
				US 2002-427670P	P 20021118
				US 2003-716183	A2 20031118
	US 2004167113	A1	20040826	US 2003-716183	20031118
				US 2002-427670P	P 20021118
	CA 2505590	A1	20041007	CA 2003-2505590	20031118
				US 2002-427670P	P 20021118
				WO 2003-US37035	W 20031118
	AU 2003303942	A1	20041018	AU 2003-303942	20031118
				US 2002-427670P	P 20021118
				WO 2003-US37035	W 20031118
	EP 1567486	A2	20050831	EP 2003-816012	20031118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				US 2002-427670P	P 20021118

JP 2006510724	T	20060330	WO 2003-US37035	W	20031118
			JP 2004-569975		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
WO 2005112916	A2	20051201	WO 2005-US17501		20050518
WO 2005112916	A3	20060216			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2007077166	A	20070329	US 2004-848836	A	20040519
			JP 2006-311085		20061117
			US 2002-427670P	P	20021118
			JP 2004-553842	A3	20031117

PATENT FAMILY INFORMATION:

FAN 2004:453170

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046092	A2	20040603	WO 2003-US36766	20031117
	WO 2004046092	A3	20040715		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500492	A1	20040603	US 2002-427670P	P	20021118
			CA 2003-2500492		20031117
			US 2002-427670P	P	20021118
			WO 2003-US36766	W	20031117
AU 2003298661	A1	20040615	AU 2003-298661		20031117
			US 2002-427670P	P	20021118
			WO 2003-US36766	W	20031117
EP 1562940	A2	20050817	EP 2003-796416		20031117
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-427670P	P	20021118
			WO 2003-US36766	W	20031117
CN 1711257	A	20051221	CN 2003-80103335		20031117
			US 2002-427670P	P	20021118
JP 2006506438	T	20060223	JP 2004-553842		20031117
			US 2002-427670P	P	20021118
			WO 2003-US36766	W	20031117
CA 2505590	A1	20041007	CA 2003-2505590		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
WO 2004085384	A2	20041007	WO 2003-US37035		20031118
WO 2004085384	A3	20050203			
WO 2004085384	A8	20050324			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003303942	A1	20041018	US 2002-427670P	P	20021118
			AU 2003-303942		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
EP 1567486	A2	20050831	EP 2003-816012		20031118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
CN 1738796	A	20060222	CN 2003-80108668		20031118
			US 2002-427670P	P	20021118
JP 2006510724	T	20060330	JP 2004-569975		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
ZA 2005003663	A	20051030	ZA 2005-3663		20050506
			US 2002-427670P	P	20021118
JP 2007077166	A	20070329	JP 2006-311085		20061117
			US 2002-427670P	P	20021118
			JP 2004-553842	A3	20031117

FAN 2005:1259748

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	WO 2005112925	A1	20051201	WO 2005-US16815	20050513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2005137193	A1	20050623	US 2004-846241	A	20040513
			US 2004-846241		20040513
			US 2002-427670P	P	20021118
			US 2003-716170	A1	20031117

FAN 2006:493928

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	US 2006111351	A1	20060525	US 2005-255163	20051020
				US 2002-427670P	P 20021118
				US 2003-716170	A2 20031117
				US 2004-846241	A2 20040513
US 2004171654	A1	20040902	US 2003-716170		20031117
US 6939885	B2	20050906			
			US 2002-427670P	P	20021118
CA 2505590	A1	20041007	CA 2003-2505590		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
AU 2003303942	A1	20041018	AU 2003-303942		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
EP 1567486	A2	20050831	EP 2003-816012		20031118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,					

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
JP 2006510724	T	20060330	JP 2004-569975		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
US 2005137193	A1	20050623	US 2004-846241		20040513
			US 2002-427670P	P	20021118
			US 2003-716170	A1	20031117
US 2005165067	A1	20050728	US 2005-46565		20050127
			US 2002-427670P	P	20021118
			US 2003-716170	A1	20031117
JP 2007077166	A	20070329	JP 2006-311085		20061117
			US 2002-427670P	P	20021118
			JP 2004-553842	A3	20031117

FAN 2007:90902

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	US 2007021466	A1	20070125	US 2006-486395		20060713
				US 2002-427670P	P	20021118
				US 2003-716170	A1	20031117
				US 2004-846241	A2	20040513
	US 2004171654	A1	20040902	US 2003-716170		20031117
	US 6939885	B2	20050906			
				US 2002-427670P	P	20021118
	CA 2505590	A1	20041007	CA 2003-2505590		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	AU 2003303942	A1	20041018	AU 2003-303942		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	EP 1567486	A2	20050831	EP 2003-816012		20031118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	JP 2006510724	T	20060330	JP 2004-569975		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	US 2005137193	A1	20050623	US 2004-846241		20040513
				US 2002-427670P	P	20021118
				US 2003-716170	A1	20031117
	US 2005165067	A1	20050728	US 2005-46565		20050127
				US 2002-427670P	P	20021118
				US 2003-716170	A1	20031117
	JP 2007077166	A	20070329	JP 2006-311085		20061117
				US 2002-427670P	P	20021118
				JP 2004-553842	A3	20031117

OS MARPAT 143:77956


AB The title compds. I [L = CO, S, SO, SO<sub>2</sub>; X = halo, alkyl, alkenyl, etc.; Y = halo, CN, NO<sub>2</sub>, etc.; Z = halo, alkyl, alkenyl, etc.] that act as potent antagonists of chemokine receptors (CCR9), were prepared Thus, reacting (2-amino-5-chlorophenyl) (phenyl)methanone with 4-tert-butylbenzenesulfonyl chloride afforded II which showed IC<sub>50</sub> < 100 nM in either or both of the chemotaxis assay and calcium mobilization assays. The compds. I are useful in pharmaceutical compns., methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

IT 855595-53-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl benzenesulfonamides as chemokine receptor CCR9 modulators)

RN 855595-53-8 CAPLUS  
 CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(methylsulfonyl)- (9CI)  
 (CA INDEX NAME)



L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1981:442562 CAPLUS  
 DN 95:42562  
 TI 2-Amino-5-mercaptobenzophenone  
 AU Gordiichuk, G. N.; Andronati, S. A.; Yavorskii, A. S.  
 CS Odessa, USSR  
 SO Khimicheskaya Promyshlennost, Seriya: Reaktivy i Osobo Chistye  
 Veshchestva (1980), (6), 5-6  
 CODEN: KSRVDF  
 DT Journal  
 LA Russian  
 AB 5,2-HS(H2N)C6H3COPh was prepared in 63% yield by treatment of  
 5,2-F2CHS(p-MeC6H4SO2NH)C6H3COPh with H2SO4.  
 IT 78211-76-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with sulfuric acid)  
 RN 78211-76-4 CAPLUS  
 CN Benzenesulfonamide, N-[2-benzoyl-4-[(difluoromethyl)thio]phenyl]-4-methyl-  
 (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1969:450004 CAPLUS  
 DN 71:50004  
 TI 7-(Alkyl- or arylthio)-5-phenyl-3H-1,4-benzodiazepin-2(1H)-ones  
 IN Keller, Oscar; Steiger, Norbert; Sternbach, Leo H.  
 PA Hoffmann-La Roche Inc.  
 SO U.S., 9 pp. Division of U.S. 3121077, U.S. 3121075, and U.S. 3121103  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	US 3442946	A	19690506	US 1963-331904	19631219

US 3371085	A	19680227	CS 1960-7357	A	19611029
			US 1961-154921		19611120
			CH 1960-13489	A	19601202
			CH 1960-13490	A	19601202
			CH 1960-13491	A	19601202
			CH 1960-13492	A	19601202
			CH 1960-13493	A	19601202
			CH 1960-13494	A	19601202
			CH 1960-13495	A	19601202
			CS 1960-7357	A	19611020

PATENT FAMILY INFORMATION:

FAN 1969:37850

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3402171	A	19680917	US 1963-326337	19631127
				CH 1960-13489	A 19601202
				CH 1960-13492	A 19601202
				CH 1960-13494	A 19601202
	US 3371085	A	19680227	US 1961-154921	19611120
				CH 1960-13489	A 19601202
				CH 1960-13490	A 19601202
				CH 1960-13491	A 19601202
				CH 1960-13492	A 19601202
				CH 1960-13493	A 19601202
				CH 1960-13494	A 19601202
				CH 1960-13495	A 19601202
				CS 1960-7357	A 19611020

FAN 1970:445551

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3515755	A	19700602	US 1968-737861	19680618
				CH 1960-13489	A 19601202
				CH 1960-13490	A 19601202
				CH 1960-13491	A 19601202
				CH 1960-13492	A 19601202
				CH 1960-13493	A 19601202
				CH 1960-13494	A 19601202
				CH 1960-13495	A 19601202
	US 3371085	A	19680227	US 1961-154921	19611120
				CH 1960-13489	A 19601202
				CH 1960-13490	A 19601202
				CH 1960-13491	A 19601202
				CH 1960-13492	A 19601202
				CH 1960-13493	A 19601202
				CH 1960-13494	A 19601202
				CH 1960-13495	A 19601202
				CS 1960-7357	A 19611020
	US 3412086	A	19681119	US 1964-406906	19641027
				CH 1960-13490	A 19601202
				CH 1960-13492	A 19601202
				CH 1960-13493	A 19601202
				CH 1960-13494	A 19601202
				CH 1960-13495	A 19601202
	US 3427304	A	19690211	US 1967-625638	19670324
				CH 1960-13489	A 19601202
				CH 1960-13490	A 19601202
				CH 1960-13491	A 19601202
				CH 1960-13492	A 19601202
				CH 1960-13493	A 19601202
				CH 1960-13494	A 19601202
				CH 1960-13495	A 19601202


AB Division of U.S. 3,121,103 (CA 61: 5671f). The disclosure is the same but the claims are different.

IT 2317-54-6P 23193-90-0P 23280-11-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 2317-54-6 CAPLUS

CN p-Toluenesulfonanilide, 4'-(methylthio)-2'-( $\alpha,\alpha,\alpha$ -trifluoro-o-toluoyl)- (7CI, 8CI) (CA INDEX NAME)




RN 23193-90-0 CAPLUS

CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- (7CI, 8CI) (CA INDEX NAME)



RN 23280-11-7 CAPLUS

CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)- (7CI, 8CI) (CA INDEX NAME)



L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1964:432524 CAPLUS

DN 61:32524

OREF 61:5672d-h, 5673a-c

TI Aminobenzodiazepines

IN Keller, Oscar; Steiger, Norbert; Sternbach, Leo H.

PA Hoffmann-La Roche Inc.

SO 9 pp.

DT Patent

LA Unavailable

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

-----

-----

-----

-----

-----

PI	US 3121075	19640211	US 1962-197853	19620528
			CS	19611020

AB The title compds. are useful as sedatives, tranquilizers, muscle relaxants, and anticonvulsants. 2-Aminobenzophenone (30 g.) and 40 g. NaCNS in 100 cc. MeOH, cooled to 0° was treated dropwise with a cold solution of 9.5 cc. Br in 35 cc. cold MeOH (saturated with NaBr) and the mixture stirred (cold) for an addnl. 0.5 hr. to give the 5-thiocyanato derivative (I), m. 83-4° (dilute EtOH). I (39 g.) in 200 cc. EtOH was heated to 50° on a steam bath, treated alternately in portions with 55 g. Na2S2O4 and 250 cc. 10% NaOH warmed to 80°, cooled to 40°, treated dropwise with 20 cc. Me2SO4, and stirred 1 hr. at room temperature to give 2-amino-5-methylthiobenzophenone (II), m. 47-9° (petr. ether). II (42 g.) was heated with 40 g. glycine Et ester-HCl (III in 75 cc. C5H5N for 6 hrs. at 118-20° to give IIIa (R = Me), (IV) m. 216-18° (Me2CO). Similarly, I with EtBr gave 2-amino-5-ethylthiobenzophenone which with III gave IIIa (R = Et), m. 273° (MeCN-EtOH). Also, I with BuBr gave 2-amino-5-butylthiobenzophenone, which with III and HCl gave IIIa.HCl (R = Bu), m. 247-9°. I with ethylene bromohydrin gave 2-amino-5-hydroxyethylthiobenzophenone which with III and HCl gave IIIa.HCl (R = HOCH2CH2), m. 252-3° (decomposition). IV with 30% H2O2 gave the sulfoxide (V), m. 254° (decomposition). p-MeSO2C6H4NH2.HCl with BzCl and ZnCl2 gave 2-amino-5-methylsulfonylbenzophenone, m. 159-61°, which with III gave IV sulforte, m. 256-8°. 2-Amino-5-chlorobenzophenone with SCl gave 4-benzyl-6-chloro-2,3,1-benzothiazathiolium chloride, which with Me2SO4 gave 2-amino-5-chloro-3-methylthiobenzophenone. This with III gave 7-chloro-9-methylthio-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one, m. 189-91°. II with NH2OH.HCl gave the oxime which with ClCH2COCl gave 6-methylthio-2-chloromethyl-4-phenylquinazoline 3-oxide (VI), m. 155-6° (CH2Cl2). VI with MeNH2 gave 7-methylthio-2-methylamino-5-phenyl-3H-1,4-benzodiazepine 4-oxide, m. 245-6°. Similarly, VI with NH3 gave the 2-amino analog. VI with N NaOH gave IV 4-oxide (VII), m. 191-3°. VII with PCl3 gave IV. V with SOCl2 gave IIIa.HCl (R = ClCH2), m. 258-60° (decomposition) (MeOH). Also prepared were 7-methylthio-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 221-3° (EtOH); 7-methylthio-5-(o-trifluoromethylphenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 199-200° (C6H6); 1-methyl derivative of IV, m. 35-45° (hexane); 7-methylthio-4,5-dihydro-5-phenyl-3H-1,4-benzodiazepin-2(1H)one, m. 150.5-2.5° (EtOH) (the 1,4-dimethyl derivative m. 96-8°); 4,5-dihydro-1,4-dimethyl-7-methylsulfinyl-5-phenyl-3H-1,4benzodiazepin-2(1H)-one, m. 160-1°; 7-chloro-5-(2-methylthiophenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 184-5°; 7-ethylsulfinyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one, m. 195-6°; 7-(α-chloroethylthio)-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one HCl, 'm. 236-8° (free base m. 195-6°). The following intermediates were also prepared: 2-tosylamino-5-methylthiobenzophenone, m. 119-20° (the 5-methylsulfinyl derivative m. 168-9°); 2-amino-5-methylsulfinylbenzophenone, m. 124-6°; 5-thiocyanato-2-amino-2'-chlorobenzophenone, m. 117-19°; 2-bromoacetamido-5-methylthio-2'-chlorobenzophenone, m. 106-8° (the 2-p-tosylamino analog m. 125-6°); 2-chloro-2'-nitrobenzophenone, m. 76-9° (the 2'-amino analog m. 58-60°); 5-thiocyanato2'-trifluoromethyl-2-aminobenzophenone, m. 117-18°; 5-methylthio-2'-trifluoromethyl-2-bromoacetamidobenzophenone, m. 104-5° (the 2-aminoacetamido analog m. 77-8°; the 2-p-tosylamino analog m. 122-3°); 2-amino-2'-trifluoromethylbenzophenone, m. 94-6°; 2-bromoacetamido-5-methylthiobenzophenone, m. 114-15°; 2'-benzoyl-2-bromo-4'-bromomethylthioacetanilide, m. 144-6°; 2-amino-5-chloro-2'-fluorobenzophenone, m. 94-5° (the 2'-methylthio analog m. 100-100.5°); 2-bromoacetamido-5-chloro-2'-methylthiobenzophenone, m. 107-8° (the 2-aminoacetamido analog m. 125-6°).


IT 2317-54-6P, p-Toluenesulfonanilide, 4'-(methylthio)-2'-

( $\alpha,\alpha,\alpha$ -trifluoro-o-toluoyl)- 23193-90-0P,  
 p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- 23280-11-7P,  
 p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)-  
 94864-13-8P, p-Toluenesulfonanilide, 2'-(o-chlorobenzoyl)-4'-(methylthio)-

RL: PREP (Preparation)  
 (preparation of)


RN 2317-54-6 CAPLUS

CN p-Toluenesulfonanilide, 4'-(methylthio)-2'-( $\alpha,\alpha,\alpha$ -trifluoro-o-toluoyl)- (7CI, 8CI) (CA INDEX NAME)




RN 23193-90-0 CAPLUS

CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- (7CI, 8CI) (CA INDEX NAME)




RN 23280-11-7 CAPLUS

CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 94864-13-8 CAPLUS

CN p-Toluenesulfonanilide, 2'-(o-chlorobenzoyl)-4'-(methylthio)- (7CI) (CA INDEX NAME)



L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1964:432523 CAPLUS  
 DN 61:32523  
 OREF 61:5671f-h,5672a-d  
 TI Benzodiazepines  
 IN Keller, Oscar; Steiger, Norbert; Sternbach, Leo H.  
 PA Hoffman-La Roche Inc.  
 SO 9 pp.  
 DT Patent  
 LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3121103		19640211	US 1962-197842	19620528
FR M2615			CS	19611020
GB 986873			FR	
			GB	

OS MARPAT 61:32523

AB To a suspension of 30 g. 2-aminobenzophenone and 40 g. NaSCN in 100 ml. MeOH, cooled to 0° was added dropwise a cold solution of 28.5 g. Br in 35 ml. MeOH saturated with NaBr, the mixture stirred 30 min., poured into 1 l. cold H<sub>2</sub>O, and neutralized with 110 ml. 20% aqueous Na<sub>2</sub>CO<sub>3</sub> to give 2-amino-5-thiocyanatobenzophenone (I), m. 83-4°. To a suspension of 39 g. I in 200 ml. EtOH heated to 55° was added, alternately, portionwise, 55 g. Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> and 250 ml. 10% aqueous NaOH, the mixture heated to 80°, cooled to 40°, 27 g. Me<sub>2</sub>SO<sub>4</sub> added dropwise, the mixture stirred 1 hr. at room temperature, the EtOH distilled, the aqueous phase diluted with 700

ml. H<sub>2</sub>O and extracted with 4 300-ml. portions C<sub>6</sub>H<sub>6</sub>, and the C<sub>6</sub>H<sub>6</sub> phase worked up to give 2-amino-5-methylthiobenzophenone (II), m. 47-9°. A mixture of 42 g. II, 40 g. glycine Et ester-HCl, and 75 ml. C<sub>5</sub>H<sub>5</sub>N was heated 6 hrs. at 118-20°, with replacement of C<sub>5</sub>H<sub>5</sub>N as it boiled off, and the product worked up to give 7-methylthio-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one, m. 21618°. Similarly were prepared the following III (R given): 7-ethylthio (HCl salt m. 273°) (MeCN-EtOH); 7-butylthio (HCl salt m. 247-9°); 7-hydroxyethylthio (HCl salt m. 252-3°) (decomposition); 7-methylsulfinyl (HCl salt m. 254°) (decomposition); 7-methylsulfonyl, m. 256-8°; 7-chloro-9-methylthio, m. 189-91°; 1-methyl-7-methylthio, m. 35-45°; 7-chloromethylthio (HCl salt m. 258-60°) (decomposition); 7-methylthio-4,5-dihydro, m. 150.52.5°; 7-methylthio-1,4-dimethyl-4,5-dihydro, m. 96-8°; 4,5-dihydro-1,4-dimethyl-7-methylsulfinyl, m. 160-1°; 7-methylthio (4-oxide), m. 191-3°; 1-methyl-7-methylthio (4-oxide); 7-ethylsulfinyl, m. 195-6°; 7-(α-chloroethylthio) (HCl salt m. 236-8°); and 7-(α-chloroethylthio), m. 195-6°. Also prepared were 2-amino-5-methylsulfonylbenzophenone, m. 159-61°; 2-amino-5-methylthiobenzophenone oxime, m. 149-50°; 6-methylthio-2-chloromethyl-4-phenylquinazoline 3-oxide, m. 155-6°; 7-methylthio-2-methylamino-5-phenyl-3H-1,4-benzodiazepine 4-oxide, m. 245-6°; 7-methylthio-2-amino-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 2-tosylamino-5-methylthiobenzophenone, m. 119-20°;


2-tosylamino-5-methylsulfinylbenzophenone, m. 168-9°;  
 2-amino-5-methylsulfinylbenzophenone, m. 124-6°;  
 5-thiocyanato-2-amino-2'-chlorobenzophenone, m. 117-19°;  
 5-methylthio-2-amino-2'-chlorobenzophenone; 2-bromoacetamido-5-methylthio-2'-chlorobenzophenone, m. 106-8°; 7-methylthio-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 221-3°; 2-(p-tosylamino)-5-methylthio-2'-chlorobenzophenone, m. 125-6°; 2-chloro-2'-nitrobenzophenone, m. 76-9°; 2-amino-2'-chlorobenzophenone, m. 58-60°; 5-thiocyanato-2'-trifluoromethyl-2-aminobenzophenone, m. 117-18°; 5-methylthio-2'-trifluoromethyl-2-aminobenzophenone; 5-methylthio-2'-trifluoromethyl-2-bromoacetamidobenzophenone, m. 104-5°; 5-methylthio-2'-trifluoromethyl-2-aminoacetamidobenzophenone, m. 77-8°; 7-methylthio-5-(o-trifluoromethylphenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 199-200°; 2-(p-tosylamino)-5-methylthio-2'-trifluoromethylbenzophenone, m. 122-3°; 2-amino-2'-trifluoromethylbenzophenone, m. 94-6°; 2-bromoacetamido-5-methylthiobenzophenone, m. 114-15°; 2'-benzoyl-2-bromo-4'-bromomethylthioacetanilide, m. 144-6°; 2-amino-5-chloro-2'-fluorobenzophenone, m. 94-5°; 2-amino-5-chloro-2'-methylthiobenzophenone, m. 100-100.5°; 2-bromoacetamido-2'-methylthio-5-chlorobenzophenone, m. 107-8°; 2-aminoacetamido-2'-methylthio-5-chlorobenzophenone, m. 125-6°; and 7-chloro-5-(2-methylthiophenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 1845°.

IT 2317-54-6P, p-Toluenesulfonanilide, 4'-(methylthio)-2'-( $\alpha,\alpha,\alpha$ -trifluoro-o-toluoyl)- 23193-90-0P,  
 p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- 23280-11-7P,  
 p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)-  
 94864-13-8P, p-Toluenesulfonanilide, 2'-(o-chlorobenzoyl)-4'-(methylthio)-

RL: PREP (Preparation)  
 (preparation of)


RN 2317-54-6 CAPLUS

CN p-Toluenesulfonanilide, 4'-(methylthio)-2'-( $\alpha,\alpha,\alpha$ -trifluoro-o-toluoyl)- (7CI, 8CI) (CA INDEX NAME)




RN 23193-90-0 CAPLUS


CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- (7CI, 8CI) (CA INDEX NAME)



RN 23280-11-7 CAPLUS  
 CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)- (7CI, 8CI) (CA  
 INDEX NAME)



RN 94864-13-8 CAPLUS  
 CN p-Toluenesulfonanilide, 2'-(o-chlorobenzoyl)-4'-(methylthio)- (7CI) (CA  
 INDEX NAME)



=>  
 Uploading C:\posullivan\183zzd.str

L12. STRUCTURE UPLOADED

=>  
 Uploading C:\posullivan\183zze.str

L13 STRUCTURE UPLOADED

=>  
 Uploading C:\posullivan\183zzf.str

L14 STRUCTURE UPLOADED

=> s l12

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 05:03:20 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 91 TO ITERATE

100.0% PROCESSED

91 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1248 TO 2392  
PROJECTED ANSWERS: 1 TO 80

L15 1 SEA SSS SAM L12

L16 1 L15

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.47	575.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

FILE 'REGISTRY' ENTERED AT 05:03:24 ON 29 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2  
DICTIONARY FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 04:38:08 ON 29 MAY 2007)

FILE 'REGISTRY' ENTERED AT 04:38:25 ON 29 MAY 2007

L1 STRUCTURE UPLOADED  
L2 STRUCTURE UPLOADED  
L3 STRUCTURE UPLOADED  
L4 0 S L1  
L5 1 SEARCH L1 FULL  
L6 0 S L2  
L7 5 SEARCH L2 FULL  
L8 0 S L3  
L9 0 SEARCH L3 FULL  
L10 6 S L5 OR L7

FILE 'CAPLUS' ENTERED AT 04:49:26 ON 29 MAY 2007

L11 5 S L10  
L12 STRUCTURE UPLOADED  
L13 STRUCTURE UPLOADED  
L14 STRUCTURE UPLOADED  
S L12

FILE 'REGISTRY' ENTERED AT 05:03:20 ON 29 MAY 2007  
L15 1 S L12

FILE 'CAPLUS' ENTERED AT 05:03:20 ON 29 MAY 2007  
L16 1 S L15

FILE 'REGISTRY' ENTERED AT 05:03:24 ON 29 MAY 2007

=> s l13  
SAMPLE SEARCH INITIATED 05:03:44 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 91 TO ITERATE

100.0% PROCESSED 91 ITERATIONS 17 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1248 TO 2392  
PROJECTED ANSWERS: 93 TO 587

L17 17 SEA SSS SAM L13

=> s l14  
SAMPLE SEARCH INITIATED 05:03:47 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 91 TO ITERATE

100.0% PROCESSED 91 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1248 TO 2392  
PROJECTED ANSWERS: 0 TO 0

L18 0 SEA SSS SAM L14

=> search l12  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 05:03:59 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1737 TO ITERATE

100.0% PROCESSED 1737 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.01

L19 2 SEA SSS FUL L12

=> search l13  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 05:04:09 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1737 TO ITERATE

100.0% PROCESSED 1737 ITERATIONS 287 ANSWERS  
SEARCH TIME: 00.00.01

L20 287 SEA SSS FUL L13

=> s l14  
SAMPLE SEARCH INITIATED 05:04:19 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 91 TO ITERATE

100.0% PROCESSED 91 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1248 TO 2392  
PROJECTED ANSWERS: 0 TO 0

L21 0 SEA SSS SAM L14

=> search l14  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 05:04:28 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1737 TO ITERATE

100.0% PROCESSED 1737 ITERATIONS 18 ANSWERS  
SEARCH TIME: 00.00.01

L22 18 SEA SSS FUL L14

=> d his

(FILE 'HOME' ENTERED AT 04:38:08 ON 29 MAY 2007)

FILE 'REGISTRY' ENTERED AT 04:38:25 ON 29 MAY 2007

L1 STRUCTURE UPLOADED  
L2 STRUCTURE UPLOADED  
L3 STRUCTURE UPLOADED  
L4 0 S L1  
L5 1 SEARCH L1 FULL  
L6 0 S L2  
L7 5 SEARCH L2 FULL  
L8 0 S L3  
L9 0 SEARCH L3 FULL  
L10 6 S L5 OR L7

FILE 'CAPLUS' ENTERED AT 04:49:26 ON 29 MAY 2007

L11 5 S L10  
L12 STRUCTURE UPLOADED  
L13 STRUCTURE UPLOADED  
L14 STRUCTURE UPLOADED  
S L12

FILE 'REGISTRY' ENTERED AT 05:03:20 ON 29 MAY 2007

L15 1 S L12

FILE 'CAPLUS' ENTERED AT 05:03:20 ON 29 MAY 2007

L16 1 S L15

FILE 'REGISTRY' ENTERED AT 05:03:24 ON 29 MAY 2007

L17 17 S L13  
L18 0 S L14  
L19 2 SEARCH L12 FULL  
L20 287 SEARCH L13 FULL  
L21 0 S L14  
L22 18 SEARCH L14 FULL

=> s l19 or l20 or l22  
L23 305 L19 OR L20 OR L22

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
515.85	1091.09

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
0.00	-3.90

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 05:04:52 ON 29 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 May 2007 VOL 146 ISS 23  
FILE LAST UPDATED: 28 May 2007 (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l23

L24 21 L23

=> d l24 fbib ab hitstr 1-21

L24 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:547250 CAPLUS  
DN 143:77956  
TI Preparation of bis-aryl sulfonamides as potent modulators of chemokine receptors  
IN Ungashe, Solomon; Wei, Zheng; Wright, J. J.; Pennell, Andrew; Premack, Brett; Schall, Thomas  
PA USA  
SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 716,183.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2005137179	A1	20050623	US 2004-848836	20040519
				US 2002-427670P	P 20021118
				US 2003-716183	A2 20031118
	US 2004167113	A1	20040826	US 2003-716183	20031118
				US 2002-427670P	P 20021118
	CA 2505590	A1	20041007	CA 2003-2505590	20031118
				US 2002-427670P	P 20021118
				WO 2003-US37035	W 20031118
	AU 2003303942	A1	20041018	AU 2003-303942	20031118
				US 2002-427670P	P 20021118

EP 1567486	A2	20050831	WO 2003-US37035	W	20031118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			EP 2003-816012		20031118
			US 2002-427670P	P	20021118
JP 2006510724	T	20060330	WO 2003-US37035	W	20031118
			JP 2004-569975		20031118
			US 2002-427670P	P	20021118
WO 2005112916	A2	20051201	WO 2003-US37035	W	20031118
WO 2005112916	A3	20060216	WO 2005-US17501		20050518
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BA, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
JP 2007077166	A	20070329	US 2004-848836	A	20040519
			JP 2006-311085		20061117
			US 2002-427670P	P	20021118
			JP 2004-553842	A3	20031117

PATENT FAMILY INFORMATION:

FAN 2004:453170

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046092	A2	20040603	WO 2003-US36766	20031117
	WO 2004046092	A3	20040715		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500492	A1	20040603	US 2002-427670P	P	20021118
			CA 2003-2500492		20031117
			US 2002-427670P	P	20021118
AU 2003298661	A1	20040615	WO 2003-US36766	W	20031117
			AU 2003-298661		20031117
			US 2002-427670P	P	20021118
EP 1562940	A2	20050817	WO 2003-US36766	W	20031117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			EP 2003-796416		20031117
			US 2002-427670P	P	20021118
CN 1711257	A	20051221	WO 2003-US36766	W	20031117
			CN 2003-80103335		20031117
JP 2006506438	T	20060223	US 2002-427670P	P	20021118
			JP 2004-553842		20031117
			US 2002-427670P	P	20021118
CA 2505590	A1	20041007	WO 2003-US36766	W	20031117
			CA 2003-2505590		20031118
			US 2002-427670P	P	20021118
WO 2004085384	A2	20041007	WO 2003-US37035	W	20031118
			WO 2003-US37035		20031118

WO 2004085384 A3 20050203  
 WO 2004085384 A8 20050324  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003303942 A1 20041018 US 2002-427670P P 20021118  
 AU 2003-303942 20031118  
 US 2002-427670P P 20021118  
 WO 2003-US37035 W 20031118  
 EP 1567486 A2 20050831 EP 2003-816012 20031118  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 US 2002-427670P P 20021118  
 WO 2003-US37035 W 20031118  
 CN 1738796 A 20060222 CN 2003-80108668 20031118  
 US 2002-427670P P 20021118  
 JP 2006510724 T 20060330 JP 2004-569975 20031118  
 US 2002-427670P P 20021118  
 WO 2003-US37035 W 20031118  
 ZA 2005003663 A 20051030 ZA 2005-3663 20050506  
 US 2002-427670P P 20021118  
 JP 2007077166 A 20070329 JP 2006-311085 20061117  
 US 2002-427670P P 20021118  
 JP 2004-553842 A3 20031117

FAN 2005:1259748

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005112925	A1	20051201	WO 2005-US16815	20050513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2005137193 A1 20050623 US 2004-846241 A 20040513  
 US 2004-846241 20040513  
 US 2002-427670P P 20021118  
 US 2003-716170 A1 20031117

FAN 2006:493928

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006111351	A1	20060525	US 2005-255163	20051020
			US 2002-427670P	P 20021118
			US 2003-716170	A2 20031117
			US 2004-846241	A2 20040513
US 2004171654	A1	20040902	US 2003-716170	20031117
US 6939885	B2	20050906		
			US 2002-427670P	P 20021118
CA 2505590	A1	20041007	CA 2003-2505590	20031118
			US 2002-427670P	P 20021118
			WO 2003-US37035	W 20031118

AU 2003303942	A1	20041018	AU 2003-303942	20031118
			US 2002-427670P	P 20021118
			WO 2003-US37035	W 20031118
EP 1567486	A2	20050831	EP 2003-816012	20031118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-427670P	P 20021118
			WO 2003-US37035	W 20031118
JP 2006510724	T	20060330	JP 2004-569975	20031118
			US 2002-427670P	P 20021118
			WO 2003-US37035	W 20031118
US 2005137193	A1	20050623	US 2004-846241	20040513
			US 2002-427670P	P 20021118
			US 2003-716170	A1 20031117
US 2005165067	A1	20050728	US 2005-46565	20050127
			US 2002-427670P	P 20021118
			US 2003-716170	A1 20031117
JP 2007077166	A	20070329	JP 2006-311085	20061117
			US 2002-427670P	P 20021118
			JP 2004-553842	A3 20031117

FAN 2007:90902

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 2007021466	A1	20070125	US 2006-486395	20060713
				US 2002-427670P	P 20021118
				US 2003-716170	A1 20031117
	US 2004171654	A1	20040902	US 2004-846241	A2 20040513
	US 6939885	B2	20050906	US 2003-716170	20031117
				US 2002-427670P	P 20021118
	CA 2505590	A1	20041007	CA 2003-2505590	20031118
				US 2002-427670P	P 20021118
				WO 2003-US37035	W 20031118
AU 2003303942	A1	20041018	AU 2003-303942	20031118	
			US 2002-427670P	P 20021118	
			WO 2003-US37035	W 20031118	
EP 1567486	A2	20050831	EP 2003-816012	20031118	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
			US 2002-427670P	P 20021118	
			WO 2003-US37035	W 20031118	
JP 2006510724	T	20060330	JP 2004-569975	20031118	
			US 2002-427670P	P 20021118	
			WO 2003-US37035	W 20031118	
US 2005137193	A1	20050623	US 2004-846241	20040513	
			US 2002-427670P	P 20021118	
			US 2003-716170	A1 20031117	
US 2005165067	A1	20050728	US 2005-46565	20050127	
			US 2002-427670P	P 20021118	
			US 2003-716170	A1 20031117	
JP 2007077166	A	20070329	JP 2006-311085	20061117	
			US 2002-427670P	P 20021118	
			JP 2004-553842	A3 20031117	

OS MARPAT 143:77956

AB The title compds. I [L = CO, S, SO, SO<sub>2</sub>; X = halo, alkyl, alkenyl, etc.; Y = halo, CN, NO<sub>2</sub>, etc.; Z = halo, alkyl, alkenyl, etc.] that act as potent antagonists of chemokine receptors (CCR9), were prepared Thus, reacting (2-amino-5-chlorophenyl)(phenyl)methanone with 4-tert-butylbenzenesulfonyl chloride afforded II which showed IC<sub>50</sub> < 100 nM in either or both of the chemotaxis assay and calcium mobilization assays. The compds. I are useful in pharmaceutical compns., methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.


IT 392305-40-7P 855595-43-6P 855595-65-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl benzenesulfonamides as chemokine receptor CCR9 modulators)


RN 392305-40-7 CAPLUS

CN Acetamide, N-[4-[[[(2-benzoyl-4-chlorophenyl)amino]sulfonyl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 855595-43-6 CAPLUS

CN Acetamide, N-[4-[[[(2-benzoyl-4-chlorophenyl)amino]sulfonyl]-2-chlorophenyl]- (9CI) (CA INDEX NAME)



RN 855595-65-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(3-pyridinylamino)- (9CI) (CA INDEX NAME)



L24 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:55027 CAPLUS

DN 142:155671

TI Preparation of arylsulfonamides for treating pain and inflammation associated with the bradykinin B1 pathway

IN Anthony, Neville J.; Lim, John Jin; Su, Dai-Shi; Wood, Michael R.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

## FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005004810	A2	20050120	WO 2004-US21018	20040630
	WO 2005004810	A3	20060824		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1643960	A2	20060412	US 2003-484498P EP 2004-756434	P 20030702 20040630
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
				US 2003-484498P WO 2004-US21018	P 20030702 W 20040630
	US 2006142612	A1	20060629	US 2005-561319 US 2003-484498P WO 2004-US21018	20051220 P 20030702 W 20040630

OS CASREACT 142:155671; MARPAT 142:155671

AB The title compds. I [A = O, CO, S, N5, CRbRc; D = COR4, (un)substituted CONH2, SO2NH2, ester group; X, Y, Z = N, C; with the proviso that 0-3 X, 0-3 Y and 0-3 Z are ring N atoms; R11, R12 = H, halo, alkyl, etc.; R2, R3 = H, halo, CN, NO2, etc.; R4 = H, alkyl, cycloalkyl, etc.; R5 = H, alkyl, arylalkyl, etc.; Rb, Rc = H, halo, alkyl, haloalkyl; with the proviso] which are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway (no data), were prepared and formulated. E.g., a 3-step synthesis of II, starting from Me 2-mercaptobenzoate and 1-fluoro-2-nitrobenzene, was given.

IT 827576-84-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylsulfonamides for treating pain and inflammation associated

with the bradykinin B1 pathway)

RN 827576-84-1 CAPLUS

CN Butanamide, N-[4-[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-chloro- (9CI)  
(CA INDEX NAME)



IT 827575-66-6P 827575-68-8P 827575-99-5P  
827576-00-1P 827576-01-2P 827576-02-3P  
827576-03-4P 827576-04-5P 827576-05-6P  
827576-06-7P 827576-07-8P 827576-08-9P  
827576-09-0P 827576-10-3P 827576-11-4P  
827576-12-5P 827576-13-6P 827576-14-7P

827576-15-8P 827576-16-9P 827576-17-0P  
827576-19-2P 827576-20-5P 827576-21-6P  
827576-22-7P 827576-23-8P 827576-24-9P  
827576-25-0P 827576-26-1P 827576-27-2P  
827576-28-3P 827576-29-4P 827576-30-7P  
827576-31-8P 827576-32-9P 827576-33-0P  
827576-34-1P 827576-35-2P 827576-36-3P  
827576-37-4P 827576-38-5P 827576-39-6P  
827576-40-9P 827576-41-0P 827576-42-1P  
827576-43-2P 827576-44-3P 827576-45-4P  
827576-46-5P 827576-47-6P 827576-48-7P  
827576-49-8P 827576-50-1P 827576-51-2P  
827576-52-3P 827576-53-4P 827576-54-5P  
827576-55-6P 827576-56-7P 827576-57-8P  
827576-58-9P 827576-59-0P 827576-60-3P  
827576-61-4P 827576-62-5P 827576-63-6P  
827576-64-7P 827576-65-8P 827576-66-9P  
827576-67-0P 827576-68-1P 827576-69-2P  
827576-70-5P 827576-71-6P 827576-72-7P  
827576-73-8P 827576-75-0P 827576-76-1P  
827576-77-2P 827576-78-3P 827576-79-4P  
827576-80-7P 827576-81-8P 827576-82-9P  
827576-83-0P 827576-85-2P 827576-86-3P  
827576-87-4P 827576-88-5P 827576-89-6P  
827576-90-9P 827576-91-0P 827576-92-1P  
827576-93-2P 827576-94-3P 827576-95-4P  
827576-96-5P 827576-97-6P 827576-98-7P  
827576-99-8P 827577-01-5P 827577-08-2P  
827577-10-6P 827577-11-7P 827577-13-9P  
827577-14-0P 827577-23-1P 827577-25-3P  
827577-29-7P 827577-30-0P 827577-35-5P  
827577-36-6P 827577-37-7P 827577-38-8P  
827577-39-9P 827577-40-2P 827577-41-3P  
827577-42-4P 827577-43-5P 827577-44-6P  
827577-45-7P 827577-46-8P 827577-47-9P  
827577-48-0P 827577-49-1P 827577-50-4P  
827577-51-5P 827577-52-6P 827577-53-7P  
827577-54-8P 827577-55-9P 827577-56-0P  
827577-57-1P 827577-58-2P 827577-59-3P  
827577-60-6P 827577-61-7P 827577-62-8P  
827577-63-9P 827577-64-0P 827577-65-1P  
827577-66-2P 827577-67-3P 827577-68-4P  
827577-69-5P 827577-70-8P 827577-71-9P  
827577-72-0P 827577-73-1P 827577-74-2P  
827577-75-3P 827577-76-4P 827577-77-5P  
827577-78-6P 827577-79-7P 827577-80-0P  
827577-81-1P 827578-26-7P 827578-27-8P  
827578-28-9P 827578-29-0P 827578-30-3P  
827578-31-4P 827578-32-5P 827578-33-6P  
827578-35-8P 827578-36-9P 827578-37-0P  
827578-38-1P 827578-39-2P 827578-40-5P  
827578-41-6P 827578-43-8P 827578-44-9P  
827578-45-0P 827578-46-1P 827578-49-4P  
827578-50-7P 827578-51-8P 827578-61-0P  
827578-62-1P 827578-63-2P 827578-64-3P  
827578-65-4P 827578-66-5P 827578-67-6P  
827578-68-7P 827578-69-8P 827578-70-1P  
827578-71-2P 827578-72-3P 827578-73-4P  
827578-74-5P 827578-75-6P 827578-77-8P  
827578-78-9P 827578-79-0P 827578-80-3P  
827578-81-4P 827578-82-5P 827578-83-6P  
827578-84-7P 827578-85-8P 827578-86-9P  
827578-87-0P 827578-88-1P 827578-89-2P  
827578-90-5P 827578-91-6P 827578-92-7P

827578-93-8P 827578-94-9P 827578-95-0P  
 827578-96-1P 827578-97-2P 827578-98-3P  
 827578-99-4P 827579-00-0P 827579-01-1P  
 827579-02-2P 827579-03-3P 827579-04-4P  
 827579-05-5P 827579-06-6P 827579-07-7P  
 827579-08-8P 827579-09-9P 827579-10-2P  
 827579-11-3P 827579-12-4P 827579-13-5P  
 827579-14-6P 827579-15-7P 827579-16-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonamides for treating pain and inflammation associated

with the bradykinin B1 pathway)


RN 827575-66-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[3-(1-piperidinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)





RN 827575-68-8 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (tetrahydro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)




RN 827575-99-5 CAPLUS

CN Carbamic acid, [1-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-3-pyrrolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827576-00-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-(9CI) (CA INDEX NAME)




RN 827576-01-2 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-(2-pyridinyl)-(9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 827576-02-3 CAPLUS  
 CN Carbamic acid, [1-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-3-piperidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 827576-03-4 CAPLUS  
 CN 1-Piperidinecarboxamide, 3-amino-N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-04-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-[[[(2-benzoylphenyl) amino] sulfonyl] phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 827576-05-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-[[[(2-benzoylphenyl) amino] sulfonyl] phenyl]-3-hydroxy- (9CI) (CA INDEX NAME)




RN 827576-06-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-[[[(2-benzoylphenyl) amino] sulfonyl] phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 827576-07-8 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[[[(2-benzoylphenyl) amino] sulfonyl] phenyl]-3-(methylamino)- (9CI) (CA INDEX NAME)




RN 827576-08-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-acetyl-N-[4-[[2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-09-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[4-[[2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 827576-10-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[4-[[2-benzoylphenyl)amino]sulfonyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 827576-11-4 CAPLUS

CN 4-Morpholinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 827576-12-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 827576-13-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 827576-14-7 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-hydroxy-gamma-oxo- (9CI) (CA INDEX NAME)




RN 827576-15-8 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-(9CI) (CA INDEX NAME)




RN 827576-16-9 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 827576-17-0 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-hydroxy-γ-oxo- (9CI) (CA INDEX NAME)




RN 827576-19-2 CAPLUS

CN 1-Piperidinepropanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-(9CI) (CA INDEX NAME)




RN 827576-22-7 CAPLUS  
 CN 1-Pyrrolidinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-  
 γ-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 827576-23-8 CAPLUS  
 CN 1-Piperidinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-  
 γ,4-dioxo- (9CI) (CA INDEX NAME)




RN 827576-20-5 CAPLUS  
 CN 1-Pyrrolidinepropanamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-  
 (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 827576-21-6 CAPLUS  
 CN 1-Piperidinebutanamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-3-  
 fluoro-γ-oxo- (9CI) (CA INDEX NAME)




RN 827576-24-9 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 827576-25-0 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-γ-oxo- (9CI) (CA INDEX NAME)




RN 827576-26-1 CAPLUS

CN 1-Piperidinepropanamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 827576-27-2 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-3,3-difluoro-γ-oxo- (9CI) (CA INDEX NAME)




RN 827576-28-3 CAPLUS

CN 1-Piperidinepropanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 827576-29-4 CAPLUS

CN 1-Piperidinepropanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-hydroxy- (9CI) (CA INDEX NAME)




RN 827576-30-7 CAPLUS

CN 4-Morpholinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-γ-oxo- (9CI) (CA INDEX NAME)




RN 827576-31-8 CAPLUS

CN 4-Morpholinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-32-9 CAPLUS

CN 1-Piperidinepropanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 827576-33-0 CAPLUS

CN 1-Piperidinepropanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,3-difluoro- (9CI) (CA INDEX NAME)




RN 827576-34-1 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,3-difluoro- (9CI) (CA INDEX NAME)




RN 827576-35-2 CAPLUS

CN 4-Thiomorpholinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-gamma-oxo-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 827576-36-3 CAPLUS

CN 1-Piperidinebutanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-  
gamma,3-dioxo- (9CI) (CA INDEX NAME)




RN 827576-37-4 CAPLUS

CN 2-Morpholinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-  
methyl- (9CI) (CA INDEX NAME)




RN 827576-38-5 CAPLUS

CN 3-Isoxazolecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-  
cyclopropyl- (9CI) (CA INDEX NAME)




RN 827576-39-6 CAPLUS

CN Imidazo[2,1-b]thiazole-6-acetamide, N-[4-[[[(2-  
benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-40-9 CAPLUS

CN 3-Isioxazolecarboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 827576-41-0 CAPLUS

CN 5-Isioxazolecarboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 827576-42-1 CAPLUS

CN 2-Furanacetamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 827576-43-2 CAPLUS  
 CN 1-Pyrrolidinepropanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 827576-44-3 CAPLUS  
 CN 5-Isoxazolecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 827576-45-4 CAPLUS


CN 3-Piperidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 827576-46-5 CAPLUS


CN 2-Furancarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827576-47-6 CAPLUS

CN 1-Piperidineacetamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)





RN 827576-48-7 CAPLUS

CN 3-Furancarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-2,2-dimethyl-5-oxo- (9CI) (CA INDEX NAME)




RN 827576-49-8 CAPLUS

CN 1H-Pyrazole-4-propanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 827576-50-1 CAPLUS  
 CN 1H-1,2,4-Triazole-1-propanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-51-2 CAPLUS  
 CN 2-Furancarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 827576-52-3 CAPLUS  
 CN 2H-Pyran-4-acetamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 827576-53-4 CAPLUS  
 CN 3-Oxazolidineacetamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 827576-54-5 CAPLUS


CN 1H-Pyrazole-1-propanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-(9CI) (CA INDEX NAME)



RN 827576-55-6 CAPLUS

CN 2-Furancarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827576-56-7 CAPLUS


CN 2-Furancarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827576-57-8 CAPLUS

CN 1H-Pyrazole-1-propanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 827576-58-9 CAPLUS

CN 1H-Benzimidazole-2-propanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-59-0 CAPLUS

CN 1H-Pyrazole-1-propanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 827576-60-3 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-61-4 CAPLUS

CN 2,1-Benzisoxazole-3-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-  
enyl]- (9CI) (CA INDEX NAME)




RN 827576-62-5 CAPLUS

CN 2-Benzothiazolepropanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-  
(9CI) (CA INDEX NAME)




RN 827576-63-6 CAPLUS

CN 3-Furancarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahyd  
ro- (9CI) (CA INDEX NAME)




RN 827576-64-7 CAPLUS


CN 2-Furancarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahyd  
ro- (9CI) (CA INDEX NAME)




RN 827576-65-8 CAPLUS  
 CN 2-Pyrrolidineacetamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-5-oxo- (9CI) (CA INDEX NAME)





RN 827576-66-9 CAPLUS  
 CN 1H-Benzimidazole-1-propanamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-67-0 CAPLUS  
 CN 4-Imidazolidineacetamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 827576-68-1 CAPLUS  
 CN 1H-Imidazole-1-acetamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-69-2 CAPLUS  
 CN 1H-Indole-2-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-  
 (9CI) (CA INDEX NAME)




RN 827576-70-5 CAPLUS  
 CN 3-Pyrrolidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-  
 oxo- (9CI) (CA INDEX NAME)




RN 827576-71-6 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 827576-72-7 CAPLUS

CN 1H-1,2,4-Triazole-1-acetamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-73-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-oxo- (9CI) (CA INDEX NAME)




RN 827576-75-0 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 827576-76-1 CAPLUS

CN Butanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4,4,4-trifluoro- (9CI) (CA INDEX NAME)




RN 827576-77-2 CAPLUS

CN Cyclohexanepropanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827576-78-3 CAPLUS

CN Butanoic acid, 4-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 827576-79-4 CAPLUS

CN Propanamide, 3-amino-N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 827576-80-7 CAPLUS

CN Propanamide, 3-(acetylamino)-N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 827576-81-8 CAPLUS

CN Carbamic acid, [3-[[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




RN 827576-82-9 CAPLUS

CN Propanamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-3-methoxy- (9CI)  
(CA INDEX NAME)




RN 827576-83-0 CAPLUS

CN Benzenepropanamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 827576-85-2 CAPLUS

CN Butanamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-4-methoxy-  
(9CI) (CA INDEX NAME)




RN 827576-86-3 CAPLUS

CN Pentanamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-5-chloro-  
(9CI) (CA INDEX NAME)




RN 827576-87-4 CAPLUS

CN Pyrazinecarboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 827576-88-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-  
(9CI) (CA INDEX NAME)




RN 827576-89-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-  
(9CI) (CA INDEX NAME)




RN 827576-90-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-  
(9CI) (CA INDEX NAME)




RN 827576-91-0 CAPLUS


CN 5-Isoxazolecarboxamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-  
(9CI) (CA INDEX NAME)




RN 827576-92-1 CAPLUS  
 CN 5-Pyrimidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]]-  
 (9CI) (CA INDEX NAME)



RN 827576-93-2 CAPLUS  
 CN Propanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]]-2,2,3,3,3-  
 pentafluoro- (9CI) (CA INDEX NAME)




RN 827576-94-3 CAPLUS  
 CN Propanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]]-3,3,3-  
 trifluoro- (9CI) (CA INDEX NAME)




RN 827576-95-4 CAPLUS

CN Acetamide, N-[4-[[[2-(4-fluorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827576-96-5 CAPLUS

CN Acetamide, N-[4-[[[2-(2,3-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827576-97-6 CAPLUS

CN Acetamide, N-[4-[[[2-(2,4-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827576-98-7 CAPLUS

CN Acetamide, N-[4-[[[2-(3-fluorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827576-99-8 CAPLUS

CN Acetamide, N-[4-[[[2-(4-chlorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827577-01-5 CAPLUS

CN Acetamide, N-[4-[[[2-(3-chlorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827577-08-2 CAPLUS

CN Acetamide, N-[4-[[[2-(2-fluorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827577-10-6 CAPLUS

CN Acetamide, N-[4-[[[2-(3,4-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI) (CA INDEX NAME)




RN 827577-11-7 CAPLUS

CN Acetamide, N-[4-[[[2-(4-methylbenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI) (CA INDEX NAME)




RN 827577-13-9 CAPLUS

CN Acetamide, N-[4-[[[2-(3,5-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI) (CA INDEX NAME)




RN 827577-14-0 CAPLUS

CN Acetamide, N-[4-[[[2-(4-nitrobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827577-23-1 CAPLUS

CN Acetamide, N-[4-[[[2-(2,5-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827577-25-3 CAPLUS

CN Acetamide, N-[4-[[[2-(4-cyanobenzoyl)phenyl]amino]sulfonyl]phenyl] - (9CI)  
(CA INDEX NAME)




RN 827577-29-7 CAPLUS

CN Acetamide, N-[4-[[[2-(4-hydroxybenzoyl)phenyl]amino]sulfonyl]phenyl] -  
(9CI) (CA INDEX NAME)




RN 827577-30-0 CAPLUS

CN Acetamide, N-[4-[[[2-(4-methoxybenzoyl)phenyl]amino]sulfonyl]phenyl] -  
(9CI) (CA INDEX NAME)




RN 827577-35-5 CAPLUS


CN Cyclohexanecarboxamide, N-[4-[[[2-(benzoylphenyl)amino]sulfonyl]phenyl] -  
(9CI) (CA INDEX NAME)




RN 827577-36-6 CAPLUS  
 CN Cyclopentanecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-37-7 CAPLUS  
 CN Cyclopropanecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-38-8 CAPLUS  
 CN Benzamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-39-9 CAPLUS  
 CN Acetamide, N-[4-[[[2-[4-(trifluoromethyl)benzoyl]phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-40-2 CAPLUS  
 CN Acetamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]-2-chlorophenyl]-(9CI)  
 (CA INDEX NAME)




RN 827577-41-3 CAPLUS  
 CN Acetamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]-2-fluorophenyl]-(9CI)  
 (CA INDEX NAME)



RN 827577-42-4 CAPLUS  
 CN [1,2,4]Triazolo[1,5-a]pyrimidine-2-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-(9CI) (CA INDEX NAME)




RN 827577-43-5 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-2-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-(9CI) (CA INDEX NAME)




RN 827577-44-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 827577-45-7 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 827577-46-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 827577-47-9 CAPLUS

CN Acetic acid, [[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 827577-48-0 CAPLUS

CN Pentanamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-methyl-2-oxo-  
(9CI) (CA INDEX NAME)




RN 827577-49-1 CAPLUS

CN 5-Thiazolecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2,4-  
dimethyl- (9CI) (CA INDEX NAME)




RN 827577-50-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-  
(9CI) (CA INDEX NAME)




RN 827577-51-5 CAPLUS

CN Acetamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-methoxy- (9CI)  
(CA INDEX NAME)




RN 827577-52-6 CAPLUS

CN Acetic acid, [[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]oxo-,  
(tetrahydro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)




RN 827577-53-7 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-  
(9CI) (CA INDEX NAME)




RN 827577-54-8 CAPLUS

CN 3-Isoxazolecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-55-9 CAPLUS

CN 1,2,5-Thiadiazole-3-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-56-0 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 827577-57-1 CAPLUS  
 CN 1H-Pyrazole-4-carboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-  
 1-methyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 827577-58-2 CAPLUS  
 CN 5-Thiazolecarboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-  
 (9CI) (CA INDEX NAME)




RN 827577-59-3 CAPLUS

CN 6-Heptynamide, N-[4-[[[2-(3-bromobenzoyl)phenyl]amino]sulfonyl]phenyl]-(9CI) (CA INDEX NAME)




RN 827577-60-6 CAPLUS

CN 4-Thiazolecarboxamide, N-[4-[[[2-(benzoylphenyl)amino]sulfonyl]phenyl]-(9CI) (CA INDEX NAME)




RN 827577-61-7 CAPLUS


CN Propanamide, N-[4-[[[2-(benzoylphenyl)amino]sulfonyl]phenyl]-2-oxo-(9CI) (CA INDEX NAME)




RN 827577-62-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-63-9 CAPLUS  
 CN Ethanediame, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 827577-64-0 CAPLUS  
 CN 2-Pyrimidinecarboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-65-1 CAPLUS  
 CN Acetamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 827577-66-2 CAPLUS

CN 5-Oxazolecarboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-  
(9CI) (CA INDEX NAME)




RN 827577-67-3 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-68-4 CAPLUS


CN Ethanediarnide, N'-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 827577-69-5 CAPLUS  
 CN 6-Heptynamide, N-[4-[[[2-(4-bromobenzoyl)phenyl]amino]sulfonyl]phenyl]-  
 (9CI) (CA INDEX NAME)




RN 827577-70-8 CAPLUS  
 CN 4-Pyridazinecarboxamide, N-[4-[[[2-(4-bromobenzoyl)phenyl]amino]sulfonyl]phenyl]-  
 (9CI) (CA INDEX NAME)



RN 827577-71-9 CAPLUS  
 CN 1H-1,2,4-Triazole-3-carboxamide, N-[4-[[[2-(4-bromobenzoyl)phenyl]amino]sulfonyl]phenyl]-  
 (9CI) (CA INDEX NAME)




RN 827577-72-0 CAPLUS  
 CN Propanamide, N-[4-[[[2-(4-bromobenzoyl)phenyl]amino]sulfonyl]phenyl]-2,2-dimethyl-  
 (9CI) (CA INDEX NAME)




RN 827577-73-1 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, N-[4-[[[(2-benzoylphenyl) amino] sulfonyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 827577-74-2 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[4-[[[(2-benzoylphenyl) amino] sulfonyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 827577-75-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[[[(2-benzoylphenyl) amino] sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-76-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827577-77-5 CAPLUS

CN Benzo[b]thiophene-3-carboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 827577-78-6 CAPLUS

CN 4-Pyridazinecarboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-3,6-dichloro- (9CI) (CA INDEX NAME)




RN 827577-79-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 827577-80-0 CAPLUS

CN 4-Isioxazolecarboxamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 827577-81-1 CAPLUS

CN 1H-Benzimidazole-2-carboxamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 827578-26-7 CAPLUS

CN Carbamic acid, [4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]-, 3-(1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)




RN 827578-27-8 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (tetrahydro-2H-pyran-2-yl)methyl ester (9CI) (CA INDEX NAME)




RN 827578-28-9 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [4-(phenylmethyl)-2-morpholinyl]methyl ester (9CI) (CA INDEX NAME)




RN 827578-29-0 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-(3-fluoro-1-piperidiny)propyl ester (9CI) (CA INDEX NAME)



RN 827578-30-3 CAPLUS


CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-(4-morpholinyl)propyl ester (9CI) (CA INDEX NAME)



RN 827578-31-4 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(2R)-tetrahydro-5-oxo-2-furanyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827578-32-5 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(2R)-5-oxo-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827578-33-6 CAPLUS


CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(2S)-5-oxo-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827578-35-8 CAPLUS


CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 2-(tetrahydro-2-furanyl)ethyl ester (9CI) (CA INDEX NAME)



RN 827578-36-9 CAPLUS


CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(2S)-tetrahydro-5-oxo-2-furanyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827578-37-0 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-(3,3-difluoro-1-piperidiny)propyl ester (9CI) (CA INDEX NAME)




RN 827578-38-1 CAPLUS  
 CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 827578-39-2 CAPLUS  
 CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (tetrahydro-3-furanyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 827578-40-5 CAPLUS  
 CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(4S)-3-(1,1-dimethylethyl)-2-oxo-4-oxazolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827578-41-6 CAPLUS


CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (2-oxo-1,3-dioxolan-4-yl)methyl ester (9CI) (CA INDEX NAME)




RN 827578-43-8 CAPLUS


CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (2-oxo-1-pyrrolidinyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A







RN 827578-44-9 CAPLUS  
 CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 2-furanylmethyl ester (9CI) (CA INDEX NAME)




RN 827578-45-0 CAPLUS  
 CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 7-oxabicyclo[2.2.1]hept-2-yl ester (9CI) (CA INDEX NAME)



RN 827578-46-1 CAPLUS  
 CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)




RN 827578-49-4 CAPLUS  
 CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 1,4-dioxan-2-ylmethyl ester (9CI) (CA INDEX NAME)




RN 827578-50-7 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (1-methyl-2-pyrrolidinyl)methyl ester (9CI) (CA INDEX NAME)




RN 827578-51-8 CAPLUS

CN Carbamic acid, [4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (1-methyl-5-oxo-2-pyrrolidinyl)methyl ester (9CI) (CA INDEX NAME)




RN 827578-61-0 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-imidazo[1,2-a]pyridin-2-ylethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-62-1 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(1H-imidazol-4-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-63-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(1-methyl-1H-imidazol-5-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-64-3 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[3-(3-fluoro-1-piperidiny)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-65-4 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[3-(4-morpholiny)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-66-5 CAPLUS

CN Benzenesulfonamide, N-[2-(4-fluorobenzoyl)phenyl]-4-[[[2-(1-piperidiny)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-67-6 CAPLUS


CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(5-methyl-1H-imidazol-4-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-68-7 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 827578-69-8 CAPLUS


CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-pyrazinyloethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-70-1 CAPLUS


CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(3-pyrrolidinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)






RN 827578-71-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1,4-dioxan-2-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-72-3 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(tetrahydro-2H-pyran-2-yl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-73-4 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(1-piperidinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-74-5 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[3-(3,3-difluoro-1-piperidinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-75-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-imidazo[2,1-b]thiazol-6-ylethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-77-8 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-78-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(tetrahydro-2-furanyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-79-0 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[3-piperidinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-80-3 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(imidazo[1,2-a]pyridin-3-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-81-4 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-82-5 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-83-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(2-pyridinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-84-7 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-85-8 CAPLUS

CN Carbamic acid, [[[4-[[[2-(4-fluorobenzoyl)phenyl]amino]sulfonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 827578-86-9 CAPLUS

CN Thiomorpholine, 4-[3-[[[4-[[[2-(benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 827578-87-0 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(tetrahydro-2H-pyran-2-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-88-1 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-pyrrolidinylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-89-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(methylamino)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-90-5 CAPLUS


CN Morpholine, 4-[3-[[[4-[[2-(benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 827578-91-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(tetrahydro-3-furanyl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 827578-92-7 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(3-pyridinyl)ethyl]amino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 827578-93-8 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-methoxyethyl]amino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 827578-94-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(3-methoxypropyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-95-0 CAPLUS

CN Piperidine, 1-[3-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 827578-96-1 CAPLUS

CN Glycine, N-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 827578-97-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1H-imidazol-4-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-98-3 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(imidazo[1,2-a]pyrimidin-2-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827578-99-4 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(1H-1,2,4-triazol-3-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-00-0 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(4-thiazolyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-01-1 CAPLUS

CN Piperidine, 1-[3-[[[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 827579-02-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(4-methyl-1H-imidazol-2-yl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-03-3 CAPLUS

CN 2-Furancarboxamide, N-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 827579-04-4 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(3-chloropropyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-05-5 CAPLUS

CN Carbamic acid, [[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 827579-06-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[1-(phenylmethoxy)carbonyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)




RN 827579-07-7 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(imidazo[1,2-a]pyridin-2-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-08-8 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1H-1,2,4-triazol-3-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-09-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(cyclohexylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-10-2 CAPLUS

CN Piperidine, 1-[3-[[[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]-3,3-difluoro- (9CI) (CA INDEX NAME)




RN 827579-11-3 CAPLUS

CN Benzenesulfonamide, 4-[[[2-(1H-benzimidazol-2-yl)ethyl]amino]carbonyl]amino]-N-(2-benzoylphenyl)- (9CI) (CA INDEX NAME)




RN 827579-12-4 CAPLUS

CN Acetamide, N-[2-[[[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 827579-13-5 CAPLUS

CN 3-Piperidinamine, 1-acetyl-N-[[[4-[[2-benzoylphenyl]amino]sulfonyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 827579-14-6 CAPLUS  
 CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(pyrazolo[1,5-a]pyridin-7-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 827579-15-7 CAPLUS  
 CN  $\beta$ -Alanine, N-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827579-16-8 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(3-pyridinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 827579-17-9P 827579-18-0P 827579-19-1P  
 827579-20-4P 827579-21-5P 827579-22-6P  
 827579-23-7P 827579-24-8P 827579-25-9P  
 827579-26-0P 827579-27-1P 827579-28-2P  
 827579-29-3P 827579-30-6P 827579-31-7P  
 827579-32-8P 827579-33-9P 827579-34-0P  
 827579-35-1P 827579-36-2P 828263-78-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonamides for treating pain and inflammation associated

with the bradykinin B1 pathway)


RN 827579-17-9 CAPLUS

CN Benzenesulfonamide, 4-[[[2-(1H-benzotriazol-1-yl)ethyl]amino]carbonyl]amino]-N-(2-benzoylphenyl)- (9CI) (CA INDEX NAME)




RN 827579-18-0 CAPLUS

CN Carbamic acid, [2-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 827579-19-1 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(propylamino)carbonyl]amino]-(9CI) (CA INDEX NAME)





RN 827579-20-4 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(3-phenylpropyl)amino]carbonyl]amino]-(9CI) (CA INDEX NAME)




RN 827579-21-5 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827579-22-6 CAPLUS  
 CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[2-(dimethylamino)ethyl]amino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 827579-23-7 CAPLUS  
 CN Acetamide, 2-[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 827579-24-8 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(ethylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)




RN 827579-25-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-chloroethyl) amino] carbonyl] amino] - (9CI) (CA INDEX NAME)




RN 827579-26-0 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(methylamino) carbonyl] amino] - (9CI) (CA INDEX NAME)




RN 827579-27-1 CAPLUS

CN Acetamide, N-[[[4-[[[(2-benzoylphenyl) amino] sulfonyl] phenyl] amino] carbonyl] - (9CI) (CA INDEX NAME)




RN 827579-28-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(cyclopropylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-29-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 827579-30-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(4-cyanophenyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-31-7 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1H-indol-5-ylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-32-8 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1,1-dimethylethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-33-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[[[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827579-34-0 CAPLUS


CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-pyridinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-35-1 CAPLUS


CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1H-indol-6-

ylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 827579-36-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 828263-78-1 CAPLUS

CN 1H-1,2,3-Triazole-1-carboxamide, N-[4-[[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



IT 628301-24-6P, N-(2-Benzoylphenyl)-4-nitrobenzenesulfonamide

827579-37-3P, 4-Amino-N-(2-benzoylphenyl)benzenesulfonamide


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylsulfonamides for treating pain and inflammation associated


with the bradykinin B1 pathway)

RN 628301-24-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-nitro- (9CI) (CA INDEX NAME)



RN 827579-37-3 CAPLUS  
 CN Benzenesulfonamide, 4-amino-N-(2-benzoylphenyl)- (9CI) (CA INDEX NAME)



L24 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:823190 CAPLUS  
 DN 141:332056  
 TI Preparation of 3-phenyl- and 3-pyridylpropenohydroxamic acid derivatives  
 as new matrix metalloprotease (MMP-3) inhibitors  
 IN Hirata, Akikage; Nishimura, Hiroshi; Katayama, Kimiko; Tamura, Koichi;  
 Amano, Hirotaka; Sugimoto, Kaori  
 PA Wakunaga Pharmaceutical Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 60 pp.  
 CODEN: JKXXAF

DT Patent  
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2004277311	A	20041007	JP 2003-69128 JP 2003-69128	20030314 20030314

OS MARPAT 141:332056

AB Disclosed are matrix metalloprotease (MMP-3) inhibitors containing 3-phenyl- and 3-pyridylacrylohydroxamic acid derivs. (I) or salts thereof [wherein R1 = H, alkyl, halo; R2 = aryl, cycloalkylaryl, (un)substituted heteroaryl; R3 = H, halo; R4 = H, each (un)substituted alkyl or alkenyl; R5 = R6CO, R6SO2, R6NHCO, R6NHC(S); wherein R6 = cycloalkyl, cyclic amino, each (un)substituted alkyl, aryl, or heteroaryl; R7 = H, protecting group; A = CH, N, N(:O)] as active ingredients. These compds. are useful for the prevention and/or treatment of chronic rheumatoid arthritis, osteoarthritis (arthrosis deformans), jaw arthritis, slipped disk, venous ulcer, diabetic ulcer, bedsore, ulcerative colitis, Crohn's disease, duodenum ulcer, dystrophic blister, herpes dermatitis, yellow ligament calcareous deposition, cancer, heart attack, and stroke. Thus, 270 mg (E/Z)-3-[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(N-oxidopyridin-3-yl)propenoic acid Et ester (preparation given) was dissolved 3 mL dioxane, treated with 2 mL 5% aqueous NaOH solution, stirred at room temperature for

1 h 40 min, distilled under reduced pressure to remove dioxane, diluted with H2O, adjusted to pH 5-6 with 5% aqueous HCl solution, and extracted with EtOAc to

give, after workup, an oil (0.19 g). The oil was dissolved in 1.5 mL DMF, successively treated with 1-hydroxybenzotriazole 76, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 114, N-methylmorpholine 50, and O-(tert-butyldimethylsilyl)hydroxylamine 123 mg and stirred for 22 h, treated with 5 mL, and extracted with CHCl3/THF (4:1) to give, after workup and silica gel chromatog., (E)-3-[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(N-oxidopyridin-3-yl)propenohydroxamic acid. (E)-3-[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(2-pyridyl)propenohydroxamic acid showed IC50 of µg/mL against 0.030 µM against MMP-3.

IT 121779-69-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of 3-phenyl- and 3-pyridylpropenohydroxamic acid derivs. as new matrix metalloprotease (MMP-3) inhibitors as preventives or remedies for diseases)

RN 121779-69-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methoxy- (9CI) (CA INDEX NAME)



L24 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:950984 CAPLUS

DN 140:5067

TI Preparation of N-heteroaryl- and N-arylbenzenesulfonamide and -heterocyclesulfonamides as chemokine CCR9 inhibitors as antiinflammatory agents

IN Fleming, Paul; Harriman, Geraldine C. B.; Shi, Zhan; Chen, Shaowu

PA Millennium Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003099773	A1	20031204	WO 2003-US16090	20030521
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2485681	A1	20031204	US 2002-383573P	P 20020524
				CA 2003-2485681	20030521
				US 2002-383573P	P 20020524
				WO 2003-US16090	W 20030521
AU 2003248549	A1	20031212	AU 2003-248549		20030521
			US 2002-383573P	P	20020524
			WO 2003-US16090	W	20030521
US 2004038976	A1	20040226	US 2003-443155		20030521
			US 2002-383573P	P	20020524
EP 1507756	A1	20050223	EP 2003-755422		20030521
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-383573P	P	20020524
			WO 2003-US16090	W	20030521
JP 2005526857	T	20050908	JP 2004-507431		20030521
			US 2002-383573P	P	20020524
			WO 2003-US16090	W	20030521
ZA 2004009131	A	20050712	ZA 2004-9131		20041111

US 2006167251	A1	20060727	US 2002-383573P	P	20020524
			US 2006-391633		20060328
			US 2002-383573P	P	20020524
JP 2006265259	A	20061005	US 2003-443155	A3	20030521
			JP 2006-124437		20060427
			US 2002-383573P	P	20020524
US 2007066823	A1	20070322	JP 2004-507431	A3	20030521
			US 2006-601025		20061117
			US 2002-383573P	P	20020524
			US 2003-443155	A1	20030521

OS MARPAT 140:5067

AB The title compds. [I; Y is C(O), O, S, S(O), or S(O)<sub>2</sub>; X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are each, independently, N or CR, provided that at least one of X<sub>1</sub>, X<sub>2</sub>, or X<sub>3</sub> is CR; R for each occurrence and R<sub>1</sub> are each, independently, H or a substituent; R<sub>6</sub> is H, an aliphatic carbonyl group, or an aliphatic ester; ring


A is substituted or unsubstituted; and Ar<sub>1</sub> and Ar<sub>2</sub> are each, independently, an (un)substituted aryl or heteroaryl] or pharmaceutically acceptable salts, solvates or hydrates thereof are prepared These compds. I can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, in particular treating or preventing an inflammatory disease or condition and to the use the compds. I in research, therapeutic, prophylactic, and diagnostic methods. CCR9 and its associated chemokine TECK, have been implicated in chronic inflammatory diseases, such as inflammatory bowel diseases. Small mol. inhibitors of the interaction between CCR9 and its ligands (e.g., TECK), such as the compds. I, are useful for inhibiting harmful inflammatory processes triggered by receptor-ligand interactions and thus are useful for treating diseases mediated by CCR9, such as chronic inflammatory diseases. For example, 14 compds. including N-(2-benzoyl-4-bromophenyl)-4-methoxybenzenesulfonamide, 5-(oxazol-5-yl)thiophene-2-sulfonic acid (2-benzoyl-4-chlorophenyl)amine inhibited the binding of human TECK to human CCR9 receptors with IC<sub>50</sub> value less than or equal to .apprx.1.0 μM.

IT 20594-91-6P 121779-69-9P 140916-44-5P  
 314054-02-9P 314054-05-2P 392305-40-7P  
 628300-37-8P 628300-42-5P 628300-47-0P  
 628300-73-2P 628300-93-6P 628300-94-7P  
 628300-99-2P 628301-03-1P 628301-07-5P  
 628301-21-3P 628301-24-6P 628301-38-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-heteroaryl- and N-arylbenzenesulfonamide and -heterocyclesulfonamides as chemokine CCR9 inhibitors as antiinflammatory agents)

RN 20594-91-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-2-nitro- (9CI) (CA INDEX NAME)



RN 121779-69-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methoxy- (9CI) (CA INDEX NAME)

11/391633

Classification: 544/224.000

Status: 71 - RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

Title: CCR9 INHIBITORS AND METHODS OF USE THEREOF

Examiner: BALASUBRAMANIAN, BALASUB

Inventor: FLEMING, PAUL, et al

GAU: 1624

Continuity/Foreign Data report

**Patent Number:** Not Issued **Issue Date:** N/A

**Title:** CCR9 INHIBITORS AND METHODS OF USE THEREOF

**No foreign data for this application.**


**Parent Data**

11/391633 (in phx)




is a division of

10/443155 (in phx)



10/443155 (in phx)




Claims Priority from Provisional  
Application

60/383573 (in phx)




**No child data for this application.**




RN 140916-44-5 CAPLUS

CN Benzenesulfonamide, N-[4-chloro-2-(2-fluorobenzoyl)phenyl]-4-nitro- (9CI)  
(CA INDEX NAME)




RN 314054-02-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-nitro- (9CI) (CA INDEX NAME)




RN 314054-05-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-methyl-3-nitro- (9CI)  
(CA INDEX NAME)




RN 392305-40-7 CAPLUS

CN Acetamide, N-[4-[[[(2-benzoyl-4-chlorophenyl)amino]sulfonyl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 628300-37-8 CAPLUS

CN Benzenesulfonamide, N-[4-chloro-2-(2-chlorobenzoyl)phenyl]-4-nitro- (9CI)  
(CA INDEX NAME)




RN 628300-42-5 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-ethyl- (9CI) (CA INDEX NAME)




RN 628300-47-0 CAPLUS

CN Benzenesulfonamide, 4-ethyl-N-[4-nitro-2-[3-(trifluoromethyl)benzoyl]phenyl]- (9CI) (CA INDEX NAME)




RN 628300-73-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-chloro- (9CI) (CA INDEX NAME)




RN 628300-93-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-(1-methylethyl)- (9CI)  
(CA INDEX NAME)




RN 628300-94-7 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-(1-methylethoxy)- (9CI)  
(CA INDEX NAME)




RN 628300-99-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(ethyldiethylamino)- (9CI)  
(CA INDEX NAME)




RN 628301-03-1 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(diethyldiethylamino)- (9CI)  
(CA INDEX NAME)




RN 628301-07-5 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(dimethylamino)- (9CI)  
(CA INDEX NAME)




RN 628301-21-3 CAPLUS

CN Benzenesulfonamide, N-[4-chloro-2-(2-methoxybenzoyl)phenyl]-4-nitro- (9CI)  
(CA INDEX NAME)




RN 628301-24-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-nitro- (9CI) (CA INDEX NAME)




RN 628301-38-2 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-[(1-methylethyl)amino]-  
(9CI) (CA INDEX NAME)



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:533368 CAPLUS  
 DN 139:230297  
 TI 1H, 13C and 15N NMR spectral and X-ray structural studies of  
 2-arylsulfonylamino-5-chlorobenzophenones  
 AU Kolehmainen, E.; Nissinen, M.; Janota, H.; Gawinecki, R.; Osmialowski, B.  
 CS Department of Chemistry, University of Jyvaeskylae, Jyvaeskylae,  
 FIN-40014, Finland  
 SO Polish Journal of Chemistry (2003), 77(7), 889-894  
 CODEN: PJCHDQ; ISSN: 0137-5083  
 PB Polish Chemical Society  
 DT Journal  
 LA English  
 AB Six 2-(4-R-phenylsulfonylamino)-5-chlorobenzophenones were prepared and  
 their 1H, 13C and 15N NMR spectra recorded and assigned. The dependence  
 between the chemical shift of the amide proton and Hammett  $\sigma$   
 substituent consts. is of the V type. Substituent effect on the chemical  
 shift of the amide nitrogen atom was found insignificant. X-ray anal.  
 shows that the terminal benzene rings in 2-(4-nitrophenylsulfonylamino)-5-  
 chlorobenzophenone are located close to each other. They are not,  
 however, parallel, dihedral angle between them being equal to 10.86 deg  
 (MP2/6-31G\*\*//HF/6-31G\*\* ab initio calcns. show this to be 20.44 deg).  
 This shows that the mutual orientation of two benzene rings in the mol. of  
 this compound is caused by the  $\pi$ - $\pi$  stacking. It is addnl. reinforced  
 by the intramol. NH...O:C hydrogen bond. Except the  
 dihedral angle between the benzene rings, X-ray determined structure of  
 2-(4-nitrophenylsulfonylamino)-5-chlorobenzophenone is very similar to  
 this optimized by the ab initio calcns.  
 IT 314054-02-9  
 RL: PRP (Properties)  
 (crystal structure; proton, carbon-13, and nitrogen-15 NMR and  
 crystallog. study of 2-arylsulfonylamino-5-chlorobenzophenones)  
 RN 314054-02-9 CAPLUS  
 CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-nitro- (9CI) (CA INDEX  
 NAME)



RE.CNT 25      THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:171844 CAPLUS  
 DN 136:232200  
 TI Preparation of propenohydroxamic acid derivatives as TACE inhibitors for treatment of sepsis, infectious and autoimmune diseases, etc.  
 IN Hirata, Terukage; Misumi, Keiji; Ito, Kenji; Inokuma, Kenichi; Katayama, Kimiko  
 PA Wakunaga Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018326	A1	20020307	WO 2001-JP7292	20010827
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-263094	A 20000831
AU	2001080167	A5	20020313	AU 2001-80167	20010827
				JP 2000-263094	A 20000831
				WO 2001-JP7292	W 20010827
CA	2423733	A1	20030214	CA 2001-2423733	20010827
				JP 2000-263094	A 20000831
				WO 2001-JP7292	W 20010827
EP	1314721	A1	20030528	EP 2001-958495	20010827
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				JP 2000-263094	A 20000831
				WO 2001-JP7292	W 20010827
US	2004029928	A1	20040212	US 2003-344898	20030226
				JP 2000-263094	A 20000831
				WO 2001-JP7292	W 20010827

OS MARPAT 136:232200

AB The title compds. I [R1 represents hydrogen, alkyl or halogeno; R2 represents cycloalkyl, aryl, heteroaryl, etc.; R3 represents hydrogen, alkenyl, etc.; R4 represents H, (un)substituted alkyl, etc.; R5 represents R6CO, R6SO2, R6NHCO or R6NHCS (wherein R6 represents alkyl, cycloalkyl, cyclic amino, aryl, heteroaryl, etc.); R7 represents hydrogen or a protective group; and A represents CH, nitrogen, etc.] are prepared I are useful as drugs for preventing and/or treating diseases such as sepsis, rheumatoid arthritis, infectious diseases, autoimmune diseases, malignant neoplasm, collagen disease, etc. E-3-[3-[N-(4-methoxybenzenesulfonyl)-N-methylaminophenyl]-3-(3-pyridyl)]propenohydroxamic acid (II) in vitro showed IC50 of 7 nM against TACE. II in vitro showed IC50 of > 10000 nM against MMP-1.


IT 121779-69-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of propenohydroxamic acid derivs. as TACE inhibitors for treatment of sepsis and infectious and autoimmune diseases)

RN 121779-69-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:567847 CAPLUS

DN 135:304135

TI Synthesis, Molecular Modeling, and Structure-Activity Relationship of  
Benzophenone-Based CAAX-Peptidomimetic Farnesyltransferase Inhibitors  
AU Sakowski, Jacek; Boehm, Markus; Sattler, Isabel; Dahse, Hans-Martin;  
Schlitzer, Martin

CS Institut fuer Pharmazeutische Chemie, Philipps-Universitaet Marburg,  
Marburg, D-35032, Germany

SO Journal of Medicinal Chemistry (2001), 44(18), 2886-2899

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 135:304135

AB Because of the involvement of farnesylated proteins in oncogenesis,  
inhibition of the protein-modifying enzyme farnesyltransferase is  
considered a major emerging strategy in cancer therapy. Here, the authors  
describe the structure-activity relationship of a novel class of  
CAAX-peptidomimetic farnesyltransferase inhibitors based on the  
benzophenone scaffold. 4'-Me, 4'-chloro, 4'-bromo, and  
4'-nitrophenylacetic acid as substituents at the 2-amino group of the  
benzophenone core structure yield farnesyltransferase inhibitors active in  
the nanomolar range. Using diphenylacetic acid in this position further  
improves activity. Benzophenone-based cysteinamide I, an example of the  
title compds., was synthesized. SEAL superimposition of I as an inhibitor  
to the enzyme-bound conformation of a CAAX-peptide shows a markedly good  
resemblance of the mol. properties of the peptide. FlexX docking of I  
confirms the good fit of the mol. into the peptide binding site of  
farnesyltransferase. The novel benzophenone-based CAAX-peptidomimetic  
substructure described here will be useful for the design of some novel  
types of farnesyltransferase inhibitors.

IT 366456-85-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)

(preparation, mol. modeling and structure-activity relationships of  
benzophenone-based CAAX-peptidomimetics as inhibitors of  
farnesyltransferase)

RN 366456-85-1 CAPLUS

CN Propanamide, 2-amino-N-[3-benzoyl-4-[[[(4-methylphenyl)sulfonyl]amino]phenyl]-3-mercapto-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 366456-92-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, mol. modeling and structure-activity relationships of benzophenone-based CAAX-peptidomimetics as inhibitors of farnesyltransferase)

RN 366456-92-0 CAPLUS

CN Carbamic acid, [(1R)-2-[[3-benzoyl-4-[[[(4-methylphenyl)sulfonyl]amino]phenyl]amino]-2-oxo-1-[[[(triphenylmethyl)thio]methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:811922 CAPLUS

DN 123:285437

TI Synthesis of substituted amides and their bioactivity

AU Wu, Jingping; Chen, Fuheng

CS Department of Applied Chemistry, Beijing Agricultural University, Beijing, 100094, Peop. Rep. China

SO Yingyong Huaxue (1995), 12(4), 80-3

CODEN: YIHUED; ISSN: 1000-0518

PB Yingyong Huaxue Bianji Weiyuanhui

DT Journal

LA Chinese


AB Thirty substituted amides e.g. 2,4-RC1C6H3NHXR1 (R = Bz, PhCHOH, R1 = substituted Ph; X = CO, SO2) have been synthesized from 5-chloro-2-aminobenzophenone. Most of the compds. showed an inhibition effect on rice growth.

IT 169263-22-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis of substituted amides and their plant growth regulator activity)

RN 169263-22-3 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-3-nitro- (9CI) (CA INDEX NAME)



L24 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:777639 CAPLUS

DN 123:198616

TI Preparation of N-sulfonylindoline derivatives with affinity for vasopressin and oxytocin receptors

IN Wagnon, Jean; de Cointet, Paul; Nisato, Dino; Plouzane, Claude; Sereadeil-Legal, Claudine; Tonnerre, Bernard

PA Elf Sanofi SA, Fr.

SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No.737,655, abandoned. CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5338755	A	19940816	US 1992-923839	19920803
				FR 1990-9778	A 19900731
				US 1991-737655	B2 19910730
				FR 1991-9908	A 19910802
	FR 2665441	A1	19920207	FR 1990-9778	19900731
	FR 2665441	B1	19921204		
	IL 114934	A	19960804	IL 1991-114934	19910730
				FR 1990-9778	A 19900731
				IL 1991-99012	A3 19910730
	HU 219351	B	20010328	HU 1971-99045	19910731
				FR 1990-9778	A 19900731
				HU 1991-2552	A 19910731
	FR 2679903	A1	19930205	FR 1991-9908	19910802
	FR 2679903	B1	19931203		
	AU 9224758	A	19930302	AU 1992-24758	19920731
	AU 658664	B2	19950427		
				FR 1991-9908	A 19910802
				WO 1992-FR758	A 19920731
	BR 9205336	A	19931116	BR 1992-5336	19920731
				FR 1991-9908	A 19910802
				WO 1992-FR758	A 19920731
	JP 06501960	T	19940303	JP 1993-503337	19920731
				FR 1991-9908	A 19910802
				WO 1992-FR758	W 19920731
	RU 2104268	C1	19980210	RU 1993-5168	19920731
				FR 1991-9908	A 19910802
				WO 1992-FR758	W 19920731
	IL 117592	A	19990411	IL 1992-117592	19920731

CZ 288173	B6	20010516	FR 1991-9908	A	19910802
			IL 1992-102703	A3	19920731
			CZ 1993-682		19920731
			FR 1991-9908	A	19910802
CA 2206776	C	20020226	CS 1993-682	A	19920731
			CA 1992-2206776		19920731
			FR 1991-9908	A	19910802
SK 283463	B6	20030805	CA 1992-2093221	A3	19920731
			SK 1993-426		19920731
			FR 1991-9908	A	19910802
NO 9301262	A	19930526	WO 1992-FR758	W	19920731
NO 180047	B	19961028	NO 1993-1262		19930401
NO 180047	C	19970205			
			FR 1991-9908	A	19910802
FI 104069	B	19991115	WO 1992-FR758	W	19920731
FI 104069	B1	19991115	FI 1993-1476		19930401
			FR 1991-9908	A	19910802
US 5397801	A	19950314	WO 1992-FR758	W	19920731
			US 1994-240360		19940510
			FR 1990-9778	A	19900731
			US 1991-737655	B2	19910730
			FR 1991-9908	A	19910802
US 5481005	A	19960102	US 1992-923839	A3	19920803
			US 1994-348150		19941128
			FR 1990-9778	A	19900731
			US 1991-737655	B2	19910730
			FR 1991-9908	A	19910802
			US 1993-923839	A3	19930803
			US 1994-240360	A3	19940510
US 5578633	A	19961126	US 1995-458614		19950602
			FR 1990-9778	A	19900731
			US 1991-737655	B2	19910730
			FR 1991-9908	A	19910802
			US 1992-923839	A3	19920803
			US 1994-240360	A3	19940510
			US 1994-348150	A3	19941128
FI 9800175	A	19980127	FI 1998-175		19980127
FI 107048	B1	20010531			
			FR 1991-9908	A	19910802
			WO 1992-FR758	W	19920731
			FI 1993-1476	A	19930401

PATENT FAMILY INFORMATION:

FAN 1992:214341

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 469984	A2	19920205	EP 1991-402123	19910730
	EP 469984	A3	19920311		
	EP 469984	B1	19951018		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FR 2665441	A1	19920207	FR 1990-9778	A 19900731
	FR 2665441	B1	19921204	FR 1990-9778	19900731
	FI 9103614	A	19920201	FI 1991-3614	19910729
	FI 97224	B	19960731		
	FI 97224	C	19961111		
				FR 1990-9778	A 19900731
CA 2048139	A1	19920201	CA 1991-2048139		19910730
CA 2048139	C	20020212			
			FR 1990-9778	A	19900731
NO 9102970	A	19920203	NO 1991-2970		19910730
NO 175254	B	19940613			
NO 175254	C	19940921			

AT 129236	T	19951115	FR 1990-9778	A	19900731
			AT 1991-402123		19910730
ES 2080922	T3	19960216	FR 1990-9778	A	19900731
			ES 1991-402123		19910730
IL 99012	A	19960723	FR 1990-9778	A	19900731
			IL 1991-99012		19910730
IL 114934	A	19960804	FR 1990-9778	A	19900731
			IL 1991-114934		19910730
			FR 1990-9778	A	19900731
AU 9181478	A	19920206	IL 1991-99012	A3	19910730
AU 645585	B2	19940120	AU 1991-81478		19910731
			FR 1990-9778	A	19900731
ZA 9106031	A	19920429	ZA 1991-6031		19910731
			FR 1990-9778	A	19900731
HU 59669	A2	19920629	HU 1991-2552		19910731
HU 220765	B1	20020528			
			FR 1990-9778	A	19900731
JP 04234361	A	19920824	JP 1991-192078		19910731
JP 3195381	B2	20010806			
			FR 1990-9778	A	19900731
KR 211434	B1	19990802	KR 1991-13249		19910731
			FR 1990-9778	A	19900731
HU 219351	B	20010328	HU 1971-99045		19910731
			FR 1990-9778	A	19900731
			HU 1991-2552	A	19910731
AU 9350473	A	19940113	AU 1993-50473		19931105
AU 664491	B2	19951116			
			FR 1990-9778	A	19900731
US 5481005	A	19960102	US 1994-348150		19941128
			FR 1990-9778	A	19900731
			US 1991-737655	B2	19910730
			FR 1991-9908	A	19910802
			US 1993-923839	A3	19930803
			US 1994-240360	A3	19940510

FAN 1993:539091

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI

EP 526348

A1

19930203

EP 1992-402213

19920803

EP 526348

B1

19980218

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE

FR 2679903

A1

19930205

FR 1991-9908

A 19910802

FR 2679903

B1

19931203

FR 1991-9908

19910802

CA 2093221

A1

19930203

CA 1992-2093221

19920731

CA 2093221

C

19980922

FR 1991-9908

A 19910802

WO 9303013

A1

19930218

WO 1992-FR758

19920731

W: AU, BR, CA, CS, FI, HU, JP, KR, NO, RU

FR 1991-9908

A 19910802

AU 9224758

A

19930302

AU 1992-24758

19920731

AU 658664

B2

19950427

FR 1991-9908

A 19910802

WO 1992-FR758

A 19920731

ZA 9205781

A

19930302

ZA 1992-5781

19920731

FR 1991-9908

A 19910802

BR 9205336

A

19931116

BR 1992-5336

19920731

FR 1991-9908

A 19910802

WO 1992-FR758

A 19920731

JP 06501960

T

19940303

JP 1993-503337

19920731

FR 1991-9908

A 19910802

WO 1992-FR758

W 19920731

LT 3064

B

19941025

LT 1992-114

19920731

FR 1991-9908


A 19910802

LV 10091	B	19950420	LV 1992-87	19920731
HU 68927	A2	19950828	FR 1991-9908	A 19910802
IL 102703	A	19970318	HU 1993-951	19920731
JP 2633085	B2	19970723	FR 1991-9908	A 19910802
RU 2104268	C1	19980210	IL 1992-102703	19920731
			FR 1991-9908	A 19910802
IL 117592	A	19990411	JP 1992-503337	19920731
			FR 1991-9908	A 19910802
CZ 288173	B6	20010516	RU 1993-5168	19920731
			FR 1991-9908	A 19910802
CA 2206776	C	20020226	WO 1992-FR758	W 19920731
			IL 1992-117592	19920731
SK 283463	B6	20030805	FR 1991-9908	A 19910802
			IL 1992-102703	A3 19920731
AT 163289	T	19980315	CZ 1993-682	19920731
ES 2117038	T3	19980801	FR 1991-9908	A 19910802
			CS 1993-682	A 19920731
NO 9301262	A	19930526	CA 1992-2206776	19920731
NO 180047	B	19961028	FR 1991-9908	A 19910802
NO 180047	C	19970205	CA 1992-2093221	A3 19920731
			SK 1993-426	19920731
			FR 1991-9908	A 19910802
			WO 1992-FR758	W 19920731
			AT 1992-402213	19920803
			FR 1991-9908	A 19910802
			ES 1992-402213	19920803
			FR 1991-9908	A 19910802
			NO 1993-1262	19930401
			FR 1991-9908	A 19910802
FI 104069	B	19991115	WO 1992-FR758	W 19920731
FI 104069	B1	19991115	FI 1993-1476	19930401
			FR 1991-9908	A 19910802
US 5481005	A	19960102	WO 1992-FR758	W 19920731
			US 1994-348150	19941128
			FR 1990-9778	A 19900731
			US 1991-737655	B2 19910730
			FR 1991-9908	A 19910802
			US 1993-923839	A3 19930803
			US 1994-240360	A3 19940510
AU 9511541	A	19950504	AU 1995-11541	19950203
AU 691223	B2	19980514		
HU 9500474	A3	19951030	FR 1991-9908	A 19910802
			HU 1995-474	19950628
			FR 1991-9908	A 19910802
FI 9800175	A	19980127	FI 1998-175	19980127
FI 107048	B1	20010531		
			FR 1991-9908	A 19910802
			WO 1992-FR758	W 19920731
			FI 1993-1476	A 19930401


OS MARPAT 123:198616

AB Title compds. I (R'1 = halo, C1-4 alkyl, HO, C1-4 alkoxy, PhCH2O, NC, F3C, O2N, H2N; R'2 = C1-6 alkyl, C3-7 cycloalkyl, C5-7 cycloalkylene, (substituted) Ph, etc.; R'3 = H; R'4 = H2NCO, R'6R'7NCO wherein R'6R'7N = saturated 5-membered substituted N-heterocyclyl; R'5 = C1-4 alkyl, 1-, 2-naphthyl, (substituted) Ph, etc.; n = m = 0-2) or a salt thereof, are prepared CH2BrCONMe2 (preparation given) and 5-chloro-2-(tosylamino)phenyl cyclohexyl ketone were reacted to give 2-[N-tosyl-N-(dimethylcarbamoylmethyl)amino]-5-(chlorophenyl) cyclohexyl ketone which in THF was treated with Li diisopropylamide to give after workup trans-I (R'1n = 5-Cl, R'2 = cyclohexyl, R'3 = H, R'4 = Me2NCO, R'5 = 4-MeC6H4, m = 0). The IC50 of I affinity for oxytocin receptors was

10-5-10-8M.  
 IT 94107-57-0P 140916-44-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of N-sulfonylindoline derivs. with affinity for vasopressin and  
 oxytocin receptors)  
 RN 94107-57-0 CAPLUS  
 CN Benzenesulfonamide, N-[2-(2-fluorobenzoyl)-4-nitrophenyl]-4-methyl- (9CI)  
 (CA INDEX NAME)



RN 140916-44-5 CAPLUS  
 CN Benzenesulfonamide, N-[4-chloro-2-(2-fluorobenzoyl)phenyl]-4-nitro- (9CI)  
 (CA INDEX NAME)



L24 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1992:214341 CAPLUS  
 DN 116:214341  
 TI Preparation of 1-arylsulfonyl-3-hydroxyindoline-2-carboxylates and analogs  
 as vasopressin and oxytocin receptor ligands  
 IN Wagnon, Jean; De Cointet, Paul; Nisato, Dino; Plouzane, Claude;  
 Serradeil-Legal, Claudine  
 PA Sanofi SA, Fr.  
 SO Eur. Pat. Appl., 44 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA French  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 469984	A2	19920205	EP 1991-402123	19910730
	EP 469984	A3	19920311		
	EP 469984	B1	19951018		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FR 2665441	A1	19920207	FR 1990-9778	A 19900731
	FR 2665441	B1	19921204	FR 1990-9778	19900731
	FI 9103614	A	19920201	FI 1991-3614	19910729

FI 97224	B	19960731		
FI 97224	C	19961111		
CA 2048139	A1	19920201	FR 1990-9778	A 19900731
CA 2048139	C	20020212	CA 1991-2048139	19910730
NO 9102970	A	19920203	FR 1990-9778	A 19900731
NO 175254	B	19940613	NO 1991-2970	19910730
NO 175254	C	19940921		
AT 129236	T	19951115	FR 1990-9778	A 19900731
ES 2080922	T3	19960216	AT 1991-402123	19910730
IL 99012	A	19960723	FR 1990-9778	A 19900731
IL 114934	A	19960804	ES 1991-402123	19910730
AU 9181478	A	19920206	FR 1990-9778	A 19900731
AU 645585	B2	19940120	IL 1991-99012	19910730
ZA 9106031	A	19920429	FR 1990-9778	A 19900731
HU 59669	A2	19920629	IL 1991-114934	19910730
HU 220765	B1	20020528	FR 1990-9778	A 19900731
JP 04234361	A	19920824	IL 1991-99012	A3 19910730
JP 3195381	B2	20010806	AU 1991-81478	19910731
KR 211434	B1	19990802	FR 1990-9778	A 19900731
HU 219351	B	20010328	ZA 1991-6031	19910731
AU 9350473	A	19940113	FR 1990-9778	A 19900731
AU 664491	B2	19951116	HU 1991-2552	19910731
US 5481005	A	19960102	FR 1990-9778	A 19900731
			JP 1991-192078	19910731
			FR 1990-9778	A 19900731
			KR 1991-13249	19910731
			FR 1990-9778	A 19900731
			HU 1971-99045	19910731
			FR 1990-9778	A 19900731
			HU 1991-2552	A 19910731
			AU 1993-50473	19931105
			FR 1990-9778	A 19900731
			US 1994-348150	19941128
			FR 1990-9778	A 19900731
			US 1991-737655	B2 19910730
			FR 1991-9908	A 19910802
			US 1993-923839	A3 19930803
			US 1994-240360	A3 19940510

PATENT FAMILY INFORMATION:

FAN 1993:539091

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526348	A1	19930203	EP 1992-402213	19920803
	EP 526348	B1	19980218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2679903	A1	19930205	FR 1991-9908	A 19910802
	FR 2679903	B1	19931203	FR 1991-9908	19910802
	CA 2093221	A1	19930203	CA 1992-2093221	19920731
	CA 2093221	C	19980922		
	WO 9303013	A1	19930218	FR 1991-9908	A 19910802
	W: AU, BR, CA, CS, FI, HU, JP, KR, NO, RU				
				WO 1992-FR758	19920731
	AU 9224758	A	19930302	FR 1991-9908	A 19910802
	AU 658664	B2	19950427	AU 1992-24758	19920731
				FR 1991-9908	A 19910802
				WO 1992-FR758	A 19920731

ZA 9205781	A	19930302	ZA 1992-5781		19920731
BR 9205336	A	19931116	FR 1991-9908	A	19910802
			BR 1992-5336		19920731
			FR 1991-9908	A	19910802
JP 06501960	T	19940303	WO 1992-FR758	A	19920731
			JP 1993-503337		19920731
			FR 1991-9908	A	19910802
LT 3064	B	19941025	WO 1992-FR758	W	19920731
			LT 1992-114		19920731
LV 10091	B	19950420	FR 1991-9908	A	19910802
			LV 1992-87		19920731
HU 68927	A2	19950828	FR 1991-9908	A	19910802
			HU 1993-951		19920731
IL 102703	A	19970318	FR 1991-9908	A	19910802
			IL 1992-102703		19920731
JP 2633085	B2	19970723	FR 1991-9908	A	19910802
			JP 1992-503337		19920731
RU 2104268	C1	19980210	FR 1991-9908	A	19910802
			RU 1993-5168		19920731
			FR 1991-9908	A	19910802
IL 117592	A	19990411	WO 1992-FR758	W	19920731
			IL 1992-117592		19920731
			FR 1991-9908	A	19910802
CZ 288173	B6	20010516	IL 1992-102703	A3	19920731
			CZ 1993-682		19920731
			FR 1991-9908	A	19910802
CA 2206776	C	20020226	CS 1993-682	A	19920731
			CA 1992-2206776		19920731
			FR 1991-9908	A	19910802
SK 283463	B6	20030805	CA 1992-2093221	A3	19920731
			SK 1993-426		19920731
			FR 1991-9908	A	19910802
AT 163289	T	19980315	WO 1992-FR758	W	19920731
			AT 1992-402213		19920803
ES 2117038	T3	19980801	FR 1991-9908	A	19910802
			ES 1992-402213		19920803
NO 9301262	A	19930526	FR 1991-9908	A	19910802
NO 180047	B	19961028	NO 1993-1262		19930401
NO 180047	C	19970205			
			FR 1991-9908	A	19910802
FI 104069	B	19991115	WO 1992-FR758	W	19920731
FI 104069	B1	19991115	FI 1993-1476		19930401
			FR 1991-9908	A	19910802
US 5481005	A	19960102	WO 1992-FR758	W	19920731
			US 1994-348150		19941128
			FR 1990-9778	A	19900731
			US 1991-737655	B2	19910730
			FR 1991-9908	A	19910802
			US 1993-923839	A3	19930803
			US 1994-240360	A3	19940510
AU 9511541	A	19950504	AU 1995-11541		19950203
AU 691223	B2	19980514			
			FR 1991-9908	A	19910802
HU 9500474	A3	19951030	HU 1995-474		19950628
			FR 1991-9908	A	19910802
FI 9800175	A	19980127	FI 1998-175		19980127
FI 107048	B1	20010531			
			FR 1991-9908	A	19910802
			WO 1992-FR758	W	19920731
			FI 1993-1476	A	19930401

FAN 1995:777639  
PATENT NO.

KIND DATE

APPLICATION NO.

DATE

PI	US 5338755	A	19940816	US 1992-923839		19920803
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				FR 1990-9778		19900731
	FR 2665441	A1	19920207			
	FR 2665441	B1	19921204			
	IL 114934	A	19960804	IL 1991-114934		19910730
				FR 1990-9778	A	19900731
				IL 1991-99012	A3	19910730
	HU 219351	B	20010328	HU 1971-99045		19910731
				FR 1990-9778	A	19900731
				HU 1991-2552	A	19910731
				FR 1991-9908		19910802
	FR 2679903	A1	19930205			
	FR 2679903	B1	19931203			
	AU 9224758	A	19930302	AU 1992-24758		19920731
	AU 658664	B2	19950427			
				FR 1991-9908	A	19910802
				WO 1992-FR758	A	19920731
	BR 9205336	A	19931116	BR 1992-5336		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	A	19920731
	JP 06501960	T	19940303	JP 1993-503337		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	RU 2104268	C1	19980210	RU 1993-5168		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	IL 117592	A	19990411	IL 1992-117592		19920731
				FR 1991-9908	A	19910802
				IL 1992-102703	A3	19920731
	CZ 288173	B6	20010516	CZ 1993-682		19920731
				FR 1991-9908	A	19910802
				CS 1993-682	A	19920731
	CA 2206776	C	20020226	CA 1992-2206776		19920731
				FR 1991-9908	A	19910802
				CA 1992-2093221	A3	19920731
	SK 283463	B6	20030805	SK 1993-426		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	NO 9301262	A	19930526	NO 1993-1262		19930401
	NO 180047	B	19961028			
	NO 180047	C	19970205			
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	FI 104069	B	19991115	FI 1993-1476		19930401
	FI 104069	B1	19991115			
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	US 5397801	A	19950314	US 1994-240360		19940510
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				US 1992-923839	A3	19920803
	US 5481005	A	19960102	US 1994-348150		19941128
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				US 1993-923839	A3	19930803
				US 1994-240360	A3	19940510
	US 5578633	A	19961126	US 1995-458614		19950602
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802

FI 9800175  
FI 107048

A 19980127  
B1 20010531

US 1992-923839 A3 19920803  
US 1994-240360 A3 19940510  
US 1994-348150 A3 19941128  
FI 1998-175 19980127  
FR 1991-9908 A 19910802  
WO 1992-FR758 W 19920731  
FI 1993-1476 A 19930401

OS MARPAT 116:214341

AB Title compds. [I; R1 = halo, alkyl, alkoxy, PhCH2O, etc.; R2 = (cyclo)alkyl, cycloalkenyl, (substituted) Ph; R3 = H, alkyl; R4 = CO2H, alkoxy, carbonyl, CO2CH2Ph, (substituted) CONH2; R5 = alkyl, naphthyl, (substituted) Ph, etc.; m, n = 0-2] were prepared. Thus, 4,2-Cl(R2CO)C6H3R (R2 = cyclohexyl) (II; R = NH2) was condensed with 1-naphthylsulfonyl chloride and the product condensed with BrCH2CO2Et to give II [R = N(CH2CO2Et)SO2R5; R5 = 1-naphthyl] which was treated with NaOMe/MeOH to give title compound III (cis and trans isomers). I had IC50 of .apprx.10-7M against oxytocin binding with a membrane preparation from pregnant rats.

IT 94107-57-0P 140916-44-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of vasopressin and oxytocin receptor

ligands)


RN 94107-57-0 CAPLUS

CN Benzenesulfonamide, N-[2-(2-fluorobenzoyl)-4-nitrophenyl]-4-methyl- (9CI)  
(CA INDEX NAME)



RN 140916-44-5 CAPLUS

CN Benzenesulfonamide, N-[4-chloro-2-(2-fluorobenzoyl)phenyl]-4-nitro- (9CI)  
(CA INDEX NAME)



L24 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1990:79440 CAPLUS

DN 112:79440

TI Preparation of benzophenones as intermediates for fluorene phthalide dyes

IN Yanagihara, Naoto; Iwakura, Ken

PA Fuji Photo Film Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01216942	A	19890830	JP 1988-41280 JP 1988-41280	19880224 19880224

AB Benzophenones, useful as intermediates for fluorene phthalide dyes used in recording materials, are prepared by treatment of nitrobenzoyl chlorides with m-phenylenediamines in the presence of Lewis catalysts.  
 p-Nitrobenzoyl chloride was treated with AlCl<sub>3</sub> in 1,2-dichloroethane at room temperature for 1 h and treated with m-Et<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NHAc at room temperature for 5 h to give 51% corresponding benzophenone derivative

IT 125317-21-7P  
 RL: IMF (Industrial manufacture); PREP (Preparation)  
 (preparation of, as intermediate for fluorene phthalide dyes)

RN 125317-21-7 CAPLUS

CN Benzenesulfonamide, N-[5-(diethylamino)-2-(4-nitrobenzoyl)phenyl]-4-methyl-  
 (9CI) (CA INDEX NAME)



L24 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1989:477578 CAPLUS

DN 111:77578

TI Nucleophilic substitutions of bischloronitroso compounds. IV. Sulfonfylamino oximes as extracting agents for copper(II)

AU Beger, J.; Neumann, R.; Gloe, K.; Muhl, P.

CS Sekt. Chem., Bergakad. Freiberg, Freiberg, DDR-9200, Ger. Dem. Rep.

SO Journal fuer Praktische Chemie (Leipzig) (1988), 330(5), 683-94  
 CODEN: JPCEAO; ISSN: 0021-8383

DT Journal


LA German

OS CASREACT 111:77578


AB RSO2NR1CR2R3CR4:NOH [I; R = Ph, 4-MeC<sub>6</sub>H<sub>4</sub>, Me, hexyl, 4-Me(CH<sub>2</sub>)<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>; R<sub>1</sub>, R<sub>4</sub> = H, Me; R<sub>2</sub> = R<sub>3</sub> = Me; R<sub>2</sub> = H, R<sub>3</sub>R<sub>4</sub> = (CH<sub>2</sub>)<sub>n</sub>, hexene-1,6-diyl, cyclopentane-1,3-diyl, decadiene-1,1-diyl; n = 3, 4, 6, 10] were obtained by treating RSO<sub>2</sub>NHR<sub>1</sub> with ClCR<sub>2</sub>R<sub>3</sub>CHR<sub>4</sub>:NOH or ClCR<sub>2</sub>R<sub>3</sub>CHR<sub>4</sub>N(O):N(O)CHR<sub>4</sub>CR<sub>2</sub>R<sub>3</sub>Cl. 4-R<sub>5</sub>C<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NHC<sub>6</sub>H<sub>4</sub>(Bz)R<sub>6</sub>-2,4 [R<sub>5</sub> = Et, OMe, OEt, O(CH<sub>2</sub>)<sub>4</sub>Me, O(CH<sub>2</sub>)<sub>9</sub>Me; R<sub>6</sub> = H, NO<sub>2</sub>] were prepared by sulfonating the amines and were converted to their oximes. Several I extracted Cu efficiently from solution

IT 24042-91-9P 121779-69-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and oximation of)

RN 24042-91-9 CAPLUS  
 CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 121779-69-9 CAPLUS  
 CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methoxy- (9CI) (CA INDEX NAME)



L24 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1988:131304 CAPLUS  
 DN 108:131304  
 TI 2-Arylsulfonamidobenzophenones and -acetophenones and their oximes  
 IN Schewe, Tankred; Rapoport, Samuel Mitja; Beger, Joerg; Kuehn, Hartmut; Binte, Hans Joachim; Slapke, Juergen  
 PA VEB Fahlberg-List, Ger. Dem. Rep.  
 SO Ger. Offen., 44 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3544409	A1	19861016	DE 1985-3544409	19851216
				DD 1984-271462	A2 19841221
	DD 251126	A1	19871104	DD 1984-271462	19841221
	CH 670389	A5	19890615	CH 1985-5505	19851223
				DD 1984-271462	A 19841221

OS CASREACT 108:131304; MARPAT 108:131304  
 AB The title compds. (I; R = Me, Ph, p-substituted Ph; R1 = H, alkyl, alkoxy, amino, acylamino; R2 = H, halo, NO2, amino, acylamino; X = O, oximino) were prepared as lipoxxygenase and cyclooxygenase inhibitors. Thus, 0.02 mol 2-(p-methoxybenzenesulfonamido)acetophenone in EtOH was treated with 0.044 mol NH2OH.HCl in pyridine and the mixture was refluxed for 3 h to give 90% I (R = Me, R1 = 4-MeO, X = NOH, R2 = H) which at 50 µM showed 80% inhibition of arachidonic acid-induced contractions in guinea pigs vs. 30% for benoxaprofen.


IT 107506-26-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as cyclooxygenase and lipoxxygenase inhibitor)

RN 107506-26-3 CAPLUS  
 CN Acetamide, N-[4-[[[2-benzoylphenyl]amino]sulfonyl]phenyl]- (9CI) (CA

INDEX NAME)



L24 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1984:34519 CAPLUS  
DN 100:34519  
TI Heterocyclic syntheses via carbanionically induced rearrangement reactions  
AU Hellwinkel, Dieter; Lenz, Ruediger; Laemmerzahl, Frank  
CS Org. Chem. Inst., Univ. Heidelberg, Heidelberg, D-6900/1, Fed. Rep. Ger.  
SO Tetrahedron (1983), 39(12), 2073-84  
CODEN: TETRAB; ISSN: 0040-4020  
DT Journal  
LA English  
OS CASREACT 100:34519  
AB The easily occurring [1.3]-migrations of sulfonyl and carbonyl functions to neighboring Ph anions can be utilized for ring expansions by one benzo unit when suitably tailored precursor heterocycles are used. Thus, 1,2-benzisothiazole dioxide I can be transformed into dibenzothiazepine dioxide II, whereas dibenzo- and 1,2,4-benzothiazin dioxides III and IV, resp., give rise to tribenzothiazocin dioxide V and dibenzothiadiazocine dioxide VI, resp. Unexpected formations of heterocyclic systems, namely, spiroisoidolobenzoxazinisobenzofuran VII, 3,1-benzoxazin VIII, and phenanthridinium salt IX took place when N-(2-bromo-4-methylphenyl)phthalimide, 2,4-BrMeC6H3NBz2, and o-PhC6H4NMeCOC6H4Me-p were reacted with Me3CLi.  
IT 88312-94-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 88312-94-1 CAPLUS  
CN Benzenesulfonamide, 2-amino-N-(2-benzoyl-4-methylphenyl)- (9CI) (CA INDEX NAME)




L24 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1980:639482 CAPLUS  
DN 93:239482  
TI 7-Amino-5-phenyl-1,4-3H-benzodiazepin-2-(1H)-one  
IN Christensen, Svend Aage  
PA A/S Dumex, Den.  
SO Dan., 6 pp.  
CODEN: DAXXAF  
DT Patent


LA Danish

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DK 142030	B	19800811	DK 1971-1079	19710309
				GB 1970-13636	A 19700320
	SE 384859	C	19780921	SE 1971-3442	19710317
				GB 1970-13636	A 19700320
	NO 134158	C	19791019	NO 1971-1059	19710318
				GB 1970-13636	A 19700320
AB	The title compound (I) was prepared by tosylating 2,4-Bz(O <sub>2</sub> N)C <sub>6</sub> H <sub>3</sub> NH <sub>2</sub> , reducing 2,4-Bz(O <sub>2</sub> N)C <sub>6</sub> H <sub>3</sub> NHSO <sub>2</sub> C <sub>6</sub> H <sub>4</sub> Me-4, treating the amine with phthalic anhydride, detosylating II (R = SO <sub>2</sub> C <sub>6</sub> H <sub>4</sub> Me-4), treating II (R = H) with phthalylglycyl chloride, and cyclizing II (R = phthalimidoacetyl) with N <sub>2</sub> H <sub>4</sub> .				
IT	37020-30-7P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction of, with phthalic anhydride)				
RN	37020-30-7	CAPLUS			
CN	Benzenesulfonamide, N-(4-amino-2-benzoylphenyl)-4-methyl- (9CI) (CA INDEX NAME)				




IT 24042-91-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reduction of)  
RN 24042-91-9 CAPLUS  
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)




L24 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1972:462035 CAPLUS  
DN 77:62035  
TI Benzophenone derivative and its conversion to a benzodiazepine derivative  
IN Christensen, Svend Age  
PA Aktieselskabet Dumex (Dumex Ltd.)  
SO Brit., 5 pp.  
CODEN: BRXXAA  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1274142		19720510	GB 1970-13636	19700320
AB	5-H <sub>2</sub> N(O <sub>2</sub> N)C <sub>6</sub> H <sub>3</sub> COPh was refluxed 1 hr with p-MeC <sub>6</sub> H <sub>4</sub> SO <sub>2</sub> Cl in pyridine to give 2,5-(p-MeC <sub>6</sub> H <sub>4</sub> SO <sub>2</sub> NH)(O <sub>2</sub> N)C <sub>6</sub> H <sub>3</sub> COPh, which was reduced by Fe to 2,5-(p-MeC <sub>6</sub> H <sub>4</sub> SO <sub>2</sub> NH)(H <sub>2</sub> N)C <sub>6</sub> H <sub>3</sub> COPh (I). Treating I with phthalic anhydride in xylene gave the phthalimide (II, R = p-MeC <sub>6</sub> H <sub>4</sub> SO <sub>2</sub> ), which was hydrolyzed to the amine (II, R = H) (III). Reacting III with phthalylglycyl chloride gave the acetamide (II, R = phthalimidoacetyl), which cyclized in the presence of (NH <sub>2</sub> ) <sub>2</sub> .H <sub>2</sub> O to give the benzodiazepine (IV).				
IT	24042-91-9P 37020-30-7P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	24042-91-9 CAPLUS				
CN	Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)				



RN	37020-30-7 CAPLUS				
CN	Benzenesulfonamide, N-(4-amino-2-benzoylphenyl)-4-methyl- (9CI) (CA INDEX NAME)				



L24 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1970:456144 CAPLUS  
 DN 73:56144  
 TI Antidiabetic dibenzo[c,g][1,2,6]thiadiazocines  
 PA Upjohn Co.  
 SO Brit., 10 pp.  
 CODEN: BRXXAA  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1193917		19700603	GB 1968-15251	19680329
				US	19670516
	DE 1770289			DE	
	FR 1584277			FR	
	US 3534062		19701013	US	19670516
AB	Title compds. (I), useful against anaphylaxis and as antidiabetic agents, as well as starting materials in the manufacture of bleaching agents, herbicides and disinfectants, were prepared Thus, 25 g 5,2-Cl(H <sub>2</sub> N)C <sub>6</sub> H <sub>3</sub> Bz				


and 23.9 g o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Cl in 50 ml pyridine was refluxed .apprx.1 hr to give 35.2 g 2'-benzoyl-4-chloro-2-nitrobenzenesulfonanilide, which was reduced (Fe powder) then treated with p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H to give I (R = R<sub>1</sub> = R<sub>2</sub> = H, R<sub>3</sub> = 2-Cl). Other I (.apprx.3) were prepared, and many other I were cited.

IT 20434-81-5P 20434-83-7P 20434-84-8P  
20594-91-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 20434-81-5 CAPLUS

CN Benzenesulfonanilide, 2-amino-2'-benzoyl-4'-chloro- (8CI) (CA INDEX NAME)




RN 20434-83-7 CAPLUS

CN Benzenesulfonanilide, 2'-benzoyl-4,4'-dichloro-2-nitro- (8CI) (CA INDEX NAME)




RN 20434-84-8 CAPLUS

CN Benzenesulfonanilide, 2-amino-2'-benzoyl-4,4'-dichloro- (8CI) (CA INDEX NAME)



RN 20594-91-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-2-nitro- (9CI) (CA INDEX NAME)



L24 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1969:523960 CAPLUS

DN 71:123960

TI 2-Amino-5-nitrobenzophenone

IN Podesva, Ctirad; Kohan, Geza

PA Delmar Chemicals Ltd.

SO Ger. Offen., 11 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 1811785	B2	19760122	DE 1968-1811785	19681129
	DE 1811785	C3	19760902		
	CA 904344	A	19720704	CA 1967-6408	A 19671129
				CA 1967-6408	19671129
	NO 130475	B	19740909	NO 1968-4688	19681125
				CA 1967-6408	A 19671129
	NL 6816857	A	19690602	NL 1968-16857	19681126
				CA 1967-6408	A 19671129
	CH 512447	A	19710915	CH 1968-512447	19681126
				CA 1967-6408	A 19671129
	US 3585238	A	19710615	US 1968-779623	19681127
				CA 1967-6408	A 19671129
	SE 367185	B	19740520	SE 1968-16269	19681128
				CA 1967-6408	A 19671129
	DK 129832	B	19741125	DK 1968-5815	19681128
				CA 1967-6408	A 19671129
	SE 386667	B	19760816	SE 1968-386667	19681128
				CA 1967-6408	A 19671129
	AT 289768	B	19710510	AT 1968-11630	19681129
				CA 1967-6408	A 19671129
	CS 149650	B2	19730725	CS 1968-8172	19681129
				CA 1967-6408	A 19671129
	FI 51473	B	19760930	FI 1968-3414	19681129
				CA 1967-6408	A 19671129
	NO 130431	B	19740902	NO 1970-1966	19700522
				CA 1967-6408	A 19671129
				NO 1968-4688	A 19681125

AB The title compound (I) was prepared in good yield, without using unduly high temperature or high pressure. A mixture of 104.6 g.

2-chloro-5-nitrobenzophenone,

231.6 g. Na salt of p-MeC<sub>6</sub>H<sub>4</sub>-SO<sub>2</sub>NH<sub>2</sub>, and 500 ml. HCONMe<sub>2</sub> was heated at 160-70° with stirring 6 hrs., the mixture cooled, poured into 2 kg.

ice and extracted with CHCl<sub>3</sub>, the extract washed with water, and the solvent distilled to give 2-(p-toluenesulfonamido)-5-nitrobenzophenone (II), m.

123-5° (MeOH). II (122.5 g.) was hydrolyzed by concentrated H<sub>2</sub>SO<sub>4</sub> at


.apprx.55° 30 min. to yield I, m. 162-3° (C<sub>6</sub>H<sub>6</sub>). Reaction

of I with phthalimidoacetyl chloride and treatment of the product with


N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave 7-nitro-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one, a very

important psychotropic agent with relatively low toxicity.


IT 24042-91-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 24042-91-9 CAPLUS  
 CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)




L24 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1968:477247 CAPLUS  
 DN 69:77247  
 TI Preparation of 2H-1,2,3-benzothiadiazine 1,1-dioxides, 11H-11,11a-dihydrobenzimidazo[1,2-b][1,2]benzisothiazole 5,5-dioxides, 6H-dibenzo[c,g][1,2,5]thiadiazocine 5,5-dioxides and 5H-dibenzo[c,g][1,2,6]thiadiazocine 6,6-dioxides  
 AU Wright, John B.  
 CS Upjohn Co., Kalazoo, MI, USA  
 SO Journal of Heterocyclic Chemistry (1968), 5(4), 453-9  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 OS CASREACT 69:77247  
 AB o-Benzoylbenzenesulfonyl chlorides (I) were prepared conveniently from aminobenzophenones by diazotization followed by reaction with SO<sub>2</sub> in the presence of Cu<sup>+</sup>, according to the general method of Meerwein. Reaction of I with hydrazine led to 4-phenyl-2H-1,2,3-benzothiadiazine 1,1-dioxides, which could be methylated and acetylated readily in the 2-position. The 2-methyl derivative was prepared by reaction of I with methylhydrazine. Catalytic hydrogenation of 6-chloro-4-phenyl-2H-1,2,3-benzothiadiazine 1,1-dioxide gave the 3,4-dihydro derivative. Reaction of I with o-phenylenediamine followed by cyclodehydration gave 11H-11,11a-dihydrobenzimidazo[1,2-b]-[1,2]benzoisothiazole 5,5-dioxides (II). One of the II derivs. in NaOH solution in the presence of MeI or benzyl chloride was transformed into 6-methyl- and 6-benzyl-5H-dibenzo[c,g][1,2,6]thiadiazocine 5,5-dioxide (III), resp. 5H-Dibenzo[c,g][1,2,6]thiadiazocine 6,6-dioxides were prepared also by cyclodehydration of 2-amino-2'-benzoylbenzenesulfonanilides.  
 IT 20434-81-5P 20434-83-7P 20434-84-8P  
 20594-91-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 20434-81-5 CAPLUS  
 CN Benzenesulfonanilide, 2-amino-2'-benzoyl-4'-chloro- (8CI) (CA INDEX NAME)




RN 20434-83-7 CAPLUS  
 CN Benzenesulfonanilide, 2'-benzoyl-4,4'-dichloro-2-nitro- (8CI) (CA INDEX NAME)



RN 20434-84-8 CAPLUS  
 CN Benzenesulfonanilide, 2-amino-2'-benzoyl-4,4'-dichloro- (8CI) (CA INDEX NAME)



RN 20594-91-6 CAPLUS  
 CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-2-nitro- (9CI) (CA INDEX NAME)



L24 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1953:27210 CAPLUS

DN 47:27210

OREF 47:4622h-i,4623a-d

TI Anthraquinone vat dyes

PA C I B A Ltd.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 680857		19521015	GB 1950-18322	19500721
AB	A new series of anthraquinone vat dyes suitable for drying and printing cellulose fibers is obtained by heating 2 mols. 1,4-diaminoanthraquinonyl 2-aryl ketone with 1 mol. of an aromatic dicarboxylic acid dichloride. Thus, fluoranthenedicarboxylic acid dichloride (I) 3.2, 1,4-diamino-2-(p-chlorobenzoyl)anthraquinone (II) 8, quinoline 5, and pyridine 5 in C6H3Cl3 225 parts, heated with stirring during 3 hrs. up to				

160° followed by further heating for 0.5 hr., gave gray needles, yellowish olive in concentrated H<sub>2</sub>SO<sub>4</sub>, dyes cotton from an olive-green vat bluish gray tints fast to Cl<sub>2</sub>, boiling, and light, and having a very high tinctorial strength in printing. An analogous new dye was obtained from I and the 3,4-dichlorobenzoyl analog of II, dyes vegetable fibers from a green vat bluish gray tints. Similar vat dyes were prepared by condensing similarly 3,9-benzanthronedicarboxylic acid dichloride (from the acid and SOCl<sub>2</sub>) with II, dyes gray tints from an olive-green vat; and (p-ClCOC<sub>6</sub>H<sub>4</sub>)<sub>2</sub> with II, dyes cotton very fast reddish blue tints. To 1,4-dichloro-2-anthraquinonecarbonyl chloride (III) 34 and pyrene 20 in o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> 250 was slowly added with stirring at 40-50° AlCl<sub>3</sub> 55, the mixture stirred 2 hrs. at 40-50° and then 1 hr. at 60-5° and decomposed with ice and HCl, the solvent removed by steam distillation, and the residue filtered off and washed with dilute aqueous Na<sub>2</sub>CO<sub>3</sub> to leave 1,4-dichloro-2-(3-pyrenoyl)anthraquinone (IV), 47 parts, brown powder, m. 249° (from o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub>). IV 15, p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NH<sub>2</sub> 140, NaOAc 22, Cu(OAc)<sub>2</sub> 0.5, and CuCl 0.5 parts, heated with stirring 1 hr. at 170-5°, and the mixture poured into H<sub>2</sub>O and boiled gave 1,4-bis(p-tolylsulfonamido)-2-(3-pyrenoyl)anthraquinone (V), brown crystalline powder. V 17 stirred 10 hrs. at 0-5° with 99% HF 150 parts, and the mixture diluted with ice and H<sub>2</sub>O gave 1,4-diamino-2-(3-pyrenoyl)-anthraquinone (VI), green-blue crystalline powder from PhCl, soluble in Me<sub>2</sub>CO

with

a blue color. 1,4-Diamino-2-naphthoylanthraquinone (VII), was prepared by a similar sequence of reactions from III 69, Cl<sub>2</sub>H<sub>8</sub> 150, and AlCl<sub>3</sub> 81 in o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> 150 parts, via 1,4-dichloro-2-naphthoylanthraquinone, m. 214° (from o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub>-toluene). Vat dyes were also obtained by the condensation of VII and I, blue-gray dyeing from a dull green vat; VII and (m-HO<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>N)<sub>2</sub>, blue dyeing from a green-olive vat; and VI and (p-HO<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>N)<sub>2</sub>, gray dyeing from a green-olive vat.

IT 874514-29-1P, p-Toluenesulfonamide, N,N'[2-(3-pyrenylcarbonyl)-1,4-anthraquinonylene]bis-


RL: PREP (Preparation)


(preparation of)

RN 874514-29-1 CAPLUS

CN p-Toluenesulfonamide, N,N'[2-(3-pyrenylcarbonyl)-1,4-anthraquinonylene]bis-(5CI) (CA INDEX NAME)

PAGE 1-A





L24 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1952:53273 CAPLUS

DN 46:53273

OREF 46:8866b-h

TI Bis(1,4-diamino-2-arylcarbonylanthraquinone)amides of aromatic dicarboxylic acids

IN Moergeli, Eduard

PA C I B A Ltd.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2598587		19520527	US 1950-174362	19500717

AB Vat dyes are prepared by treating 2 mols. of a 1,4-diamino-2-anthraquinonyl 2-aryl ketone, of which the aryl radical may contain substituents, with one mol. of a reactive derivative of an aromatic dicarboxylic acid. A mixture of 3.2 parts of fluoranthenedicarbonyl dichloride (I) (British patent 533,963 (C.A. 36, 1190.7)), 1,4-diamino-2-(p-chlorobenzoyl)anthraquinone (II) 8, quinoline 5, pyridine 5, and 225 parts by volume of trichlorobenzene (III) are heated to 160° while stirring in the course of 3 hrs. Stirring is continued 1/2 hr. and a dye seps. in the form of gray needles. The dye is soluble in concentrated H2SO4 with a yellowish olive color; dyes cotton

from an olive-green vat a blueish gray tint which is fast to Cl, boiling, and light, and has a good strength in prints. I similarly reacts with 1,4-diamino-2-(3,4-dichlorobenzoyl)anthraquinone in a mixture of quinoline and III at 160° to give a more bluish tinted gray dye than that above. 6-bz-1-Benzanthronedicarbonyl dichloride and 1,4-diamino-2-(p-chlorobenzoyl)anthraquinone gives a dye coloring cotton fast gray tints from an olive-green vat. 4,4'-Biphenyldicarbonyl chloride (IV) and 1,4-diamino-2-(p-chlorobenzoyl)anthraquinone give a cotton vat dye of reddish blue tint. Use of terephthalic acid dichloride in place of IV in the last example gives a blue dye. Other vat dyes prepared from 2 mols of an anthraquinone component and 1 mol. of acid component are as follows: II and 4,4'-azobenzenedicarboxylic acid (V) give a gray; II and 3,3'-azobenzenedicarboxylic acid (VI) give a reddish blue; II and 2,6-naphthalenedicarboxylic acid give a reddish blue; II and thianthrenedicarboxylic acid (U.S. patent 2,338,516 (C.A. 38, 3851.2)) give a reddish blue; II and 2,6-benzanthronedicarboxylic acid give a reddish blue-gray; II and 2,-8-chrysenedicarboxylic acid give a violet-gray; 1,4-di-amino-2-benzoylanthraquinone and I give a bluish gray; 1,4-diamino-2-p-toluylanthraquinone and I give a gray; 1,4-diamino-2-anisoylanthraquinone and I give a gray; 1,4-diamino-2-naphthoylanthraquinone (VII) and I give a blue-gray; VII and VI give a blue; 1,4-diamino-2-(3-pyrenoyl)-anthraquinone (VIII) and V give a gray. VIII is prepared as follows: 1,4-dichloro-2-(3-pyrenecarbonyl)anthraquinone (IX), brown powder, m. 249° (after crystallization from o-dichlorobenzene) is prepared by the action of AlCl3 on 1,4-dichloro-2-anthraquinonecarbonyl chloride (X) and pyrene. IX 15 parts, p-toluenesulfonamide (XI) 140,


NaOAc 22, Cu(OAc)<sub>2</sub> 0.5, and Cu<sub>2</sub>Cl<sub>2</sub> 0.5 are heated 1 hr. at 170-5°, the water-soluble constituents are extracted with boiling water. The product is crystallized from aqueous pyridine to give a brown crystallization powder of 1,4-bis(p-tolylsulfonamido)-2-(3-pyrenecarbonyl)anthraquinone (XII). XII 17 is hydrolyzed in 99% HF 150 by stirring 10 hrs. at 0-5°. VIII is then precipitated by addition of ice and water and is purified by extracting with boiling aqueous NH<sub>3</sub> solution; then crystallizing from chlorobenzene. VIII is an acetone-soluble, blue-green crystallization powder. VII is prepared by the action of AlCl<sub>3</sub> on X and naphthalene to give, first 1,4-dichloro-2-naphthoylanthraquinone, m. 214°, which is then treated as above with XI and then hydrolyzed to give VII.

IT 874514-29-1P, p-Toluenesulfonamide, N,N'[2-(3-pyrenylcarbonyl)-1,4-anthraquinonylene]bis-  
 RL: PREP (Preparation)  
 (preparation of)

RN 874514-29-1 CAPLUS

CN p-Toluenesulfonamide, N,N'[2-(3-pyrenylcarbonyl)-1,4-anthraquinonylene]bis-  
 (5CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

